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Osteosarcoma is one of the most commonly occurred primary 
malignant bone tumor affecting children and young adults. With the 
improvement of chemotherapeutic regimes, adjuvant chemotherapy and 
surgical technique, both the successful rate of long term survival and the 
quality of life of the patients are improved. However, the need of a plasma 
biochemical marker to monitor the response of treatment also becomes more 
important 
In this research, we tested the possibility of using plasma bone-specific 
alkaline phosphatase (BALP) as a tumor marker for osteosarcoma. Firstly, we 
established the normal reference value of plasma BALP level in local Chinese 
population. The normal reference values of plasma BALP decline across the 
age, with normal range of 73.6 VfL to 217.7 U/L in age below 12 (N1); 21.7 
U/L to 136.8 U/L in age between 12 to 16 (N2) and 8.9 U/L to 59.5 U/L in age 
above 16 CN3). 
We found that plasma BALP activity of the osteosarcoma patients at 
admission (BALP-adm) is significantly higher than the normal groups 
(p<0.005). When age-match comparison is made, we found that at least in two 
age groups, namely age between 12 to 16 and age above 16, the plasma 
BALP-adm is significantly higher than the normal group (p<0.01). 
Moreover, patients with poor clinical outcome had a significantly 
higher plasma BALP-adm compared to other patients. Patients who died of 
disease within one, two and three years have a significantly higher plasma 
BALP-adm than patients who remained disease-free (p<0.05). In addition, 
plasma BALP-adm can reflect the chance of local recurrence after the surgical 
treatment. Patients who experience local relapse have a significantly higher 
plasma BALP-adm values than others (p <0.001). 
viii 
Of most clinical importance, plasma BALP level reflects the patients' 
responsiveness in the treatment processes , therefore allowing the monitoring 
of the disease. The change of plasma BALP level during the chemotherapy 
correlate well to the responsiveness of the patients toward the chemotherapy. 
Reflected by the degree of tumor necrosis, patients with their plasma BALP 
level drops back within the normal range have a significantly higher tumor 
necrosis (p < 0.05). Moreover, the change of plasma BALP level correlates 
well to the clinical observation of the patients. Except in patients with 
incomplete removal of the tumor (including metastases), the plasma BALP 
level always drops back to low level after the operation and elevated during 
recurrence. 
Ectopic expression of placental ALP was found in human osteosarcoma 
cell line U-2 OS by biochemical differentiation, isoelectric focusing separation 
and immunohistostaining. Comparing with the ALP extracted from Sa OS-2 
cell which contains solely BALP (Farley et al, 1989), the ALP expressed in U-
2 OS cells is thermostable, sensitive to L-phenylalanine inhibition but 
insensitive to levamisole inhibition and can bind to monoclonal antibody 
against human placental ALP. However, no such ectopic expression of 
placental ALP could be found in our 14 osteosarcoma patients' plasma and 
tissue extracts and 7 osteosarcoma tissue sections. 
ix 




Among the malignant tumors of the skeleton in children and 
adolescents, osteosarcoma are particularly important because of their high 
incidence and a great chance of successful treatment using chemotherapy in 
combination with surgery. 
Osteosarcoma is a new term most authors used to replace the term 
'osteogenic sarcoma,. It is defined by World Health Organization (WHO) as 
"a malignant tumor characterized by the direct formation of bone or osteoid 
by the proliferation tumor cells,, (Schajowicz, 1994). 
This definition is based on the usually readily recognizable product of 
this neoplasm. Nevertheless, even small foci of tumor osteoid within a 
predominantly chondroblastic, fibroblastic, histolytic of osteoclastic tumor 
give the diagnosis of osteosarcoma (Figure 1.1). 
1.1.2 Incidence, Geographic patterns of distribution and epidemiological 
consideration 
Excluding plasma cell myeloma, osteosarcoma is the most frequent 
primary malignant bone tumor. In United State, there are 600 to 800 new 
cases per year (Himelstein & Dormans, 1996). However, the true incidence of 
bone tumor in general, osteosarcoma in particular, is difficult to estimate 
because the population-based tumor registries record too few bone cancer 
cases to permit separation into the various types. 
In 1971, the Swedish National Cancer Registry reported an annual 
incidence of 0.28 cases per 100,000 people with no geographic difference 
(Larsson & Lorentzon, 1974). However, studies in Malaysia shows both 
geographic and radical difference in incidence rate of osteosarcoma with 0.11 
case per 100,000 people in Malays and 0.23 cases in Chinese and Indian 





Figure 1.1 Osteosarcoma with marked calcified osteoid 




1.1.3 Age, Sex and Sites 
Osteosarcoma can occur at any age, although it is chiefly an affliction 
of the young. There is evidence that age, sex and the anatomical site of 
osteosarcoma correlate well with the periods of rapid growth. 
The age and sex distribution of osteosarcoma in Memorial Sloan-
Kettering Cancer Center is shown in Figure 1.2. (Huvos, 1991). The total 
number of cases collected is 685. The tumor occurs more often in males, with 
402 males patients (58.6%) and 283 females (41.3%), which agrees with the 
general male predominance in most other studies (Dahlin & Unni，1986; 
Campanacci, 1990; Schajowicz, 1994). The higher incidence of tumors in 
men may be related to the longer period of skeletal growth and the additional 
volume of bone produced compare with the female. It is also notable that 
osteosarcoma tends to start at an earlier age in females than in males and 
patients affected by osteosarcoma have been found to be taller than their pecrs 
in the corresponding age group and also with high plasma somatomedin levels 
(McMaster, 1977). All these data show that the age period with highest 
appearance of osteosarcoma is coincided with the periods of sudden burst of 
skeletal growth. 
Approximately 10 percent of all osteosarcoma arise in patients older 
than 60, causing part of second "hump" in bimodal age distribution curve of 
the patients (Huvos, 1986,1991). Unlike those younger patients, with 97% of 
osteosarcoma are newly arise, osteosarcoma in this group of patients were 
more frequently (56%) secondary to other bony conditions, such as Paget's 
disease, or followed irradiation. 
In majority of the patients, especially the younger one, osteosarcoma 
shows a preference for the long bones. Its occurrence has a predilection for 
the metaphyseal areas of the lower end of the femur, the upper end oftibia and 
less frequently, the upper end of the humerus, that is, close to the most 
actively growing epiphyses. Approximately one-half of all tumors affected 
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the knee region, and the femur was the most common bone involved (Figure 
1.3). 
In contrast to osteosarcoma in children and adolescents, the knee joint 
region is involved in only 14.5% of the older patients. In this latter group, the 
axial skeleton was the most commonly affected (27%), in addition to the 
craniofacial bones and extraskeletal sites (Huvos, 1986). In conclusion, before 
the cessation of the growth period, the long bones are the most frequently 
involved in osteosarcoma. After this growth period, the long and the fiat 
bones are about equally affected (Huvos, 1991). 
1.1.4 Type and Grade 
Osteosarcoma covers a wide spectrum of lesion with distinct clinical 
and pathologic features, associated with different biological behavior. Two 
fundamental groups can be clearly distinguished namely, the central 
(medullary) and the surface (peripheral) osteosarcoma, depending on the site 
ofthe lesions (Schajowicz, 1983). 
Since the diagnosis of osteosarcoma is only based on the detection of 
tumor bone or osteoid, even when the predominant tissue is cartilaginous or 
fibroblastic, the lesion will still be considered as osteosarcoma. Several 
researchers tried to subdivide the osteosarcoma into different subtypes in or(ier 
to give a more precise description of the lesions. Dahlin (1978) subdivided 
osteosarcoma into three categories, depending on the predominant 
differentiation of the tumor cells. They are the “osteoblastic osteosarcoma" 
with large amount of tumor bone and osteoid production; "chondroblastic 
osteosarcoma" in which the tumor cells show predominant differentiation 
toward cartilage; and “fibroblastic osteosarcoma", in which tumor cells show 
predominant spindle-cell pattern similar to that seen in fibrosarcoma. 
A system of staging the musculosketetal neoplasm was adapted by the 
American Joint Committee Task Force on Bone Tumors in 1985 and proposed 
by them to the international Union Against Cancer for international usage 
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(Table 1.1). This system is based on the interrelationship of three factors: 
Grade (G), Site (T) and Metastasis (M). This system serves as a usefiil guide 
in the selection of an appropriate treatment and definitive surgical procedure 
(Enneking, 1986; Kems & Simon, 1983; Wolf& Enneking, 1996). 
1.1.4.1Grade 
The Grade is an assessment of the biologic aggressiveness of the lesion. 
It combines the histological assessment, radiographic assessment and the 
clinical aspect. The three stratification of grade are Go (Benign), G j (Low-
grade malignant) and G2 (High-grade malignant). 
1.1.4.2Site 
There are three strata of the anatomical setting : Tg, T^ and T2 . Both 
To and T{ are intracompartmental. For To , the lesion remains confined 
within the intact capsule while for T j , the lesion has extracapsular extension 
but all the lesions are within an anatomic compartment bounded by the natural 
barriers to tumor extension (Intracompartmental). In T2 , lesion extends 
beyond compartmental barriers into the loosely bounded fasical planes and 
space that have no longitudinal boundaries (extracompartmental). 
1.1.4.3Metastasis 
There are only two strata of metastasis : Mo and Mi. Mo indicates no 
dence of regional or distant metastasis, whereas M j signifies either regional or 
distant metastasis. 
Malignant lesions that are designated by Roman numerals : I, II, II are 
synonymy with low-grade, high-grade and metastasis. These three stages of 
sarcoma are further stratified into A and B depending on whether the lesion is 
anatomically intracompartmental (A) or extracompartmental (B). The 
characteristics of these malignant lesions are shown in Table 1.1. In 




















































































































































































































































































































































































































































































































































1.1.5 Histological Features 
Osteosarcoma can be divided into histologic subtypes of fibroblastic, 
chondroblastic, osteoblastic, telangiectatic and mixed, on the basis of the 
predominant cell formation or the pattern of growth in the lesion. Different 
subtypes of osteosarcoma reveal a significant degree of expression in alkaline 
phosphatase. The chondrosarcoma and the fibrosarcoma can be separated 
from the chondroblastic and fibroblastic osteosarcoma by the absence of 
alkaline phosphatase immunohistostaining (Table 1.2). 
1.1.6 Clinical Features 
The most common clinical symptoms of osteosarcoma is pain at tumor 
site, often irradiating to the neighboring joint, which begin insidiously and 
intermittently. The pain then progresses to severe, constant pain and is not 
relieved by rest, immobilization or ordinary analgesics. Swelling of the 
affected part and limitation of joint motion were later developed. The 
symptoms will be more predominant if there is a pathological fracture. 
However, pathological fracture is not common and is usually found in the 
predominantly osteolytic lesions. 
Local inflammatory signs and venous stasis often occur in advanced 
lesions. The duration of symptoms prior to diagnosis is extremely variable, 
averaging not more than a few months. 
Most of the patients draw their attention to their pre-existing bone 
lesion through their injuries. Ewing (1935) referred to this occurrence as 
"traumatic determination", i.e., trauma reveals more malignant growths than it 
products. 
Approximately 10-20% of the patients presents with clinically evident 
metastasis at diagnosis, most commonly in the lungs (Marina et. al., 1992). 
The prognosis continues to be poor in these patients. 
9 
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Table 1.2. Immunohistochemical finding in different subtypes of 
osteosarcoma in comparison with other chondroid tissue. 
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1.1.7 Radiological Features 
The first diagnostic test for a patient with suspected malignant bone 
tumor is a plain radiograph. Radiographs of osteosarcoma may show lytic or 
mixed lytic and destructive lesions, sometimes with calcification evidence of 
new bone formation. 
Most of the osteosarcoma arise centrally, destroy the cortex bone and 
invade the surrounding soft tissue, resulting the classic reactions exhibited by 
the periosteum. The most common radiolofical features are produced after 
these processes. The earliest recognizable radiographic change includes 
minimal irregular periosteal new bone formation in the metaphyeal, with the 
underlying bone exhibiting a localized motterled radiolucent or radiopaque 
area and periosteal reaction may appear as a fine "sunburst" or a sing]e 
vertical periosteal layer (Figure 1.4). 
In advanced stage, definite cortical destruction and breakthrough can be 
seen clearly. Moreover, there is obvious periosteal elevation, so called 
"Codman's triangle", and spicule formation (Figure 1.5). Codman's triangle is 
a manifestation of extreme periosteal elevation forming an acute angle with 
the cortex. However, the periosteal new bone formation is just a reactive 
response to the lifting of the periosteum and is not specific for osteosarcoma 
since it may be seen in Ewing's tumor as well. 
Other than plain radiography, modern imaging technique, such as 
computed tomography (CT) and the magnetic resonance imaging (MRI), also 
play important role in diagnosis and monitoring of the osteosarcoma. CT 
examination is mainly applied in appendicular and axial skeleton. It is helpfjl 
for guidance of the biopsy and to establish the intramedullary extent of the 
tumor and demonstrate the presence of skip metastasis (Hubbard, 1983). 
Magnetic resonance imaging accurately assesses tumor size and the extent of 
intramedullary tumor involvement. 
11 
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Figure 1.4 Male/22, osteosarcoma of upper tibial end, X-ray 
radiography showing "sunbrust" peristeal reaction 
(Schajowicz, 1994). 
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Figure 1.5. Male/13, Osteosarcoma of lower metaphysis of femur, 
X-ray radiograhy showing foramtion of typical 
Codman's triangle (Schajowicz, 1994). 
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1.1.8 Molecular genetics 
Most osteosarcoma harbor complex and multiple genetic aberrations, 
with characteristically bizarre karotypes (Biegel et. al., 1989). Patients with 
heritable retinoblastoma who bear constitutional mutations or losses at the 
retinoblastoma gene locus have a much higher chance of osteosarcoma. Loss 
of heterozygosity at the retinoblastoma gene locus on chromosome 13q and 
allelic loss or mutation in p53 gene in the short arm of chromosome 17 is a 
common finding in patients with osteosarcoma (Wadayama et al., 1994). 
Allelic losses on the long arms of chromosome 3 and 18 and amplifications of 
the SAS-MDM2 locus on chromosome 12q are frequently found in 
osteosarcoma too (Tarkkanen et. al., 1995). The retinoblastoma and p53 gene 
products, known as tumor suppressers, are important regulators of cell cycle, 
whereas MDM2 gene product interacts with p53 in cell cycle regulation. 
1.1.9 Treatment 
Prior to 1970, complete surgical excision was the only treatment option 
available to achieve tumor control prior to the development of adequate 
radiation therapy and chemotherapy. Unfortunately, even with the compleie 
resection of the tumor, local (95%) and systemic recurrence rates (80 - 9C%) 
were very high (Campanacci & Laus, 1980; McKenna et al., 1966) and cure 
rate is low, varying from 5 to 17% (Marcove et. al., 1970). 
Adjuvant chemotherapy for osteosarcoma was initiated in the early 
1970s. The results from these early adjuvant chemotherapy trials were very 
encouraging. Adjuvant chemotherapy consists of using anti-neoplastic drugs 
after local control of the tumor by surgery or radiation. It decreases 
metastases by eliminating mircometastic tumor deposits that may be present in 
the lungs, bone, bone marrow, lymph nodes and other sites. Moreover, the 
primary tumor size is reduced so that the subsequent surgery or radiation 
treatment for local control is technically easier, allowing limb salvage 
13 
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(preservation of the extremity) and allograft reconstruction possible (Eilber et. 
al., 1984). 
With the current regime of combine adjuvant chemotherapy and 
surgical treatment in osteosarcoma, the diseases-free survival for 
osteosarcoma has been improved dramatically compared with the historical 
controls. Approximately 60% to 65% of patients with non-metastasis 
osteosarcoma of the extremity survive without evidence of recurrence (Velez-
Yanguas & Warrier, 1996). The majority of current regimens incorporate 
adriamycin, cisplatin, and high-dose methotrexate (HDMTX). 
With the improvement of both the survival and the quality of 
osteosarcoma patients, the need for a sensitive biochemical marker is raised. 
A sensitive biochemical marker allows us to identify patients with poor 
prognosis, monitoring the patients' response to treatment and detect early local 
recurrence or metastasis of the tumor. 
1.2 Biochemical Markers of Osteosarcoma 
1.2.1 Tumor Marker 
Tumor marker is broadly defined to include any tumor-associated cell 
surface antigen or intracellular protein. They are often refers to substances in 
blood or body fluids of patients with cancer (Bates & Longo，1987). 
For an ideal biochemical marker in cancer, the marker should be 
produced solely by the tumor cells and be readily detectable in body fluids. It 
should not be present in healthy individual or patients with benign disease. 
The quantity of tumor marker should directly reflect the bulk of malignancy 
and correlate with the results of anticancer therapy. It should be present 
frequently enough and early enough in the development of a malignancy to be 
useful for screening. No marker described to date meets all of these criteria, 
but a marker will still have its clinical values if it can perform certain 
functions such as following the course of therapy and detecting recurrence. 
14 
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To examine the clinical value of a biochemical marker, several 
questions should be answered. Concerning the measurement itself, what 
method of measurement can be used? What is the sensitivity and specificity 
of the assay? Will a cross-reacting substance give false positive results and 
what is the lower limitation of the assay? 
In addition, the incidence rate of elevation of the marker should be high 
and the increase in the level of marker should relate to the stage of cancer and 
the prognosis of disease. The level of marker should also tell the physician 
whether the therapy has been effective and the normalization of the marker 
should indicate that all malignant disease has been eliminated. 
1.2.2 Biochemical markers of bone turnover 
The most commonly employed biochemical markers in bone activity 
are listed in Table 1.3. It consist of substances or molecules released into tlie 
circulation during the formation or resorption ofbone. 
For bone formation markers, serum osteocalcin is associated with the 
initiation of mineralization. It is the most abundant non-collagenous protein in 
the mineralized bone matrix and it is involved in the mineralization process of 
the bone (Akesson, 1995). Procollagen I C-terminal extension peptide (PICP) 
is released from the procollagen during the synthesis of type I collagen. Since 
collagen synthesis precedes mineralization, the amount of PILC molecule 
reflects the amount of mineralized bone (Risteli & Risteli, 1992). 
Hydroxyproline, pyridinoline and telopeptides are the degradation 
product of collagen during the bone resorption and liberated into the 
circulation. They are all removed from kidney and thus their level are greatly 
affected by the kidney function (Epstein, 1988). 
Of all biochemical markers in bone turnover, serum alkaline 
phosphatase (ALP) is the most widely used. ALP was clustered at the surface 
of the osteoblasts and is responsible for the mineralization process (Anderson, 
1989). 
15 
Bone Formation Bone Resorption 
Serum / Plasma Alkaline Urine Hydroxyproline 
Phosphatase 
Serum Osteocalcin Urine Pyridinoline 
Serum Procollagen I C-terminal 
Extension Peptide 
Table 1.3. Biochemical markers o fbone turnover. 
16 
ln1rr,rlnr,lion 
1.2.3 Change of biochemical marker in osteosarcoma 
Davies et al (1991) compared the effectiveness of several biochemical 
markers of bone turnover in monitoring of osteosarcoma. These markers 
included serum ALP level, serum osteocalcin and urinary hydroxylproline. 
By measuring these biochemical markers in a 65-year-old woman with 
osteosarcoma in right knee, they found that serum osteocalcin and 
hydroxylproline did not show any response to the onset of osteosarcoma. 
Whereas serum ALP increased rapidly during relapse and returned to low 
level after the resection of tumor (Figure 1.6). This suggested that serum 
alkaline phosphatase should be a better choice as a biochemical marker of 
osteosarcoma. 
1.3 Alkaline Phosphatase (ALP) 
Alkaline phosphatase (EC 3.1.3.1) is a trivial name of a family of 
isozymes with similar catalytic properties that hydrolyze a large variety of 
phosphomonoesters at a rather high pH, usually pH 8 to 10.7 
orthophosphoric-monoester phosphohydrolase (alkaline optimum)]. This 
enzyme is widely distributed in nature and is found in large range of 
organisms from plant, algae to vertebrates. 
ALP is a metalloenzyme with zinc being an integral part of the 
molecule. The native enzyme has four zinc atoms, two responsible for the 
catalytic activity while the other two are for the structural integrity. Other 
than zinc, serine is also presents in the active site and take part in the catalytic 
reaction. In addition, inorganic phosphate is also an integral part of the 
enzyme (McComb et al., 1979). The 3-dimensional structure of the ALP is 
illustrated in Figure 1.7. 
Most ALP exists in dimer form with molecular weight ranging from 
70,000 to 180,000. Moreover, many mammalian enzymes contain relatively 
large amounts of carbohydrates, especially sialic acid. Eukaryotic ALP are 
membrane-bound enzymes anchored to the exterior of the cytoplasmic 
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membrane via a novel complex structure identified as the glyco.^yl 
phosphatidylinositoI (GPI) anchor (Howard et. al., 1987; Wong & Low, 1992; 
McComb etal., 1979). 
1.3.1 ALPs Family 
In mammals, ALP consists a group of true isozyme encoded for at least 
four different gene loci: The L/B/K locus determines the so-called 
liver/bone/kidney of "tissue specific" ALP and is expressed in vitally all 
tissues. This L/B/K gene is located at the end of the short arm of chromosome 
1, bands p36.1-p34 (Weiss et. al., 1988). The other three are the tissue 
specific ALP genes, i.e. intestinal ALP (IALP), placental ALP (PALP) and 
germ cell ALP (GCALP). They are clustered at the end of the long arm of 
chromosome 2, bands q34-37, while a single nonspecific ALP gene is locatx;d 
at the end of the short arm of chromosome 1，bands p36.1-p34 (Millan & 
Fishman, 1995). As their name stated, they are only expressed in the specific 
tissue or only in trace amount in other tissues. The whole family of the ALP 
isozymes was shown in Figure 1.8. 
The close association of these three loci of the tissue specific ALP 
presumably reflects their common, comparatively recent, evolutionary 
ancestry. The three tissue specific ALP genes and their products have 
correspondingly similar sequences ofbases and amino acids; these similarities 
are particularly marked in the placental and germ cell ALP with 98% protein 
homology. The homology between the intestinal and placental ALP is 86.5% 
but only 56.6% to the tissue nonspecific ALP (Moss, 1992). The enzymes are 
synthesized as propeptides varying in length from 524 in L/BA( ALP to 535 in 
the placental and germ-cell ALP (Millan, 1988). 
The reasons for the characteristic differences in the expression of the 
various loci in different tissues, and indeed in different cells within the same 
tissue, are not known. In the purest sense of the term, intestinal, placental and 
tissue-nonspecific ALPs is true isozymes because their amino acid sequence 
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are different. For the tissue-nonspecific ALP isoforms, such as liver- and 
bone-specific ALP, difference arises from the post-translational modifications 
of the same gene product. Thus strictly speaking, they are considered as 
isoform but not isozyme. 
The amino acid sequences of the L/K/B isozymes are highly 
homologous, displaying 90% to 98% identity. On the other hand, the tissue 
specific ALP is only 50% to 60% homologous with any each other (Millan & 
Fishman, 1995). 
Much less is known about the structures of the carbohydrate moieties of 
these glycoproteins. Differential glycosylation of the tissue-nonspecific ALP 
gives rise to tissue-specific isoform. These sugar moieties are believed to 
protect the enzyme from the rapid removal from the circulation through 
binding by the asialoglycoprotein receptors of the liver (Komoda & Sakagishi， 
1978). It is known that the carbohydrate side chain ofIALP is not terminated 
by sialic acid. Moreover, the carbohydrate moieties of liver-specific ALP 
(LALP) and bone-specific ALP (BALP) may depend on the way sialic acid 
and the 0-linked sugar chain are linked to the molecules (Miura et. al, 1994). 
1.3.2 Membrane Binding 
ALP is anchored to the membrane by a phosphatidylinositol glycari 
(GPI) which is covalently-link to the carboxyl-terminus of the peptide chrin 
(Figure 1.9). The two fatty acyl residues of a molecule of phosphatidic acid 
are inserted into the outer layer of the membrane where they are non-
covalently anchored by hydrophobic interactions with the lipid components of 
the membrane (Low & Zilversmit, 1980). 
ALP is released from the tissues into the serum in a variety of 
pathological and physiological situations. Several mechanisms of release of 
GPI-anchored ALP molecules can be envisaged. ALP is nonspecifically 
released by detergent-mediated solubilization, in which the ALP released from 
the membranes with its GPI-anchor intact. This form of release is able to 
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undergo post-release aggregated, either with themselves or with other 
hydrophobic molecules, result in a high Mr isoform of ALP. For example, 
bile provides a favorable environment for ALP-lipid complexion and the ALP 
in bile is predominantly present as high M^ isoform (Moss, 1994; Raymond et. 
al., 1991). 
Another means of ALP release is by specific enzyme mediated 
cleavage of covalent bond of the GPI anchor. The GPI linkage of ALP is 
susceptible to cleavage by two phosphatidylinositol-specific phospholipases C 
and D (PI-PLC of PI-PLD) (Figure 1.10). Phospholipase can promote the 
solubilization of ectoenzyme from cell in vitro and releasing the hydrophilic 
form of ALP. PIPLC appears to be principally an intracellular enzyme and 
active PIPLD is present in human plasma (Davitz et. al., 1987) and it is this 
enzyme that is thought to be involved directly or indirectly in the 
solubilization of GPI-linked proteins from cell membrane. 
Since proteolytic cleavage is unlikely to contribute directly to the 
solubilization of ectoenzyme from cell surfaces, it is believed ALP released in 
serum through the following steps: ALP is solubilized from the biliary and 
plasma surfaces of hepatocytes by detergent action or membrane turnover. 
PIPLC in plasma removes phosphatidic acid and renders the ALP more 
hydrophilic low Mj. form. 
1.3.3 Biochemical Function and Physiological Role of ALP 
The in vivo functions of ALP are believed to be (Price, 1993): 
1. Phosphohydrolysis of organ phosphomonoesters of low molecular mass; 
2. Phosphotransferase activity; 
3. Protein phosphatase activity. 
ALP has little preference for a particular substrate and will hydrolyze 
all phosphomonoester. Hydrolysis of phosphomonoester proceeds via 
cleavage of 0-P binds with an activation energy of 6000 � 1 0 , 0 0 0 cal/mol 
following first order and zero-order kinetics. Catalysis includes 
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phophorylation of a serine residue at the active site, followed by transfer of the 
phosphoryl group to either water (phosphohydolysis) or an organic acceptor-
alcohol (phosphotransferase) with the transphosphorylation more preferred 
because of the hydrophobic nature of the plasma membrane-bound ALP 
(Stinson etal., 1987). 
The endogenous substrates of ALP are believed to be: 
phosphoethanolamine (PEA), inorganic pyrophosphate (PPi) and pyridoxal 0'-
phosphate (PLP) (Russell, 1965; Whyte et al., 1995). The widely distribution 
of ALP in nature suggested that this enzyme is involved in fundamental 
biochemical processes. The suggested physiology functions of ALP are listed 
below, with special description in bone-specific ALP. 
Embryonic development and cell differentiation — One of these 
fundamental processes may be embryonic development and cell 
differentiation, in which ALP guide the migration of the embryonic cell. It is 
believed that the GCALP interact with the extracellular matrix proteins and 
therefore serve as the cell guidance molecule during migration of germ cells 
down the gential ridge. 
Regulation of lipid transport ~ Intestinal ALP may be involved in lipid 
transport in the intestine, with the absorption of the lipid which bind to the 
intestinal ALP. 
Regulation of renal phosphate transport ~ ALP is indirectly involved in the 
transport of the Pi, evidenced by the decrease of Pi reabsorbance in kidney 
after the administration of the ALP inhibitors (Petitclerc & Plante, 1981). 
Moreover, ALP activity is highest in the early proximal tubule in kidney 
where Pi transport is the highest. 
Transport of IgG molecule during pregnancy - PALP permits the 
transmission of functional antibodies to the fetus through the placenta by 
acting as a Fc receptor (Makiya et. al., 1982). 
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Regulation of pancreatic chloride channels - Membrane bound ALP plays 
an important role in the regulation of a phosphorylated low-conductance 
chloride channel in human pancreatic duct cells (Becq et al., 1993). 
Metabolism of PLP in Brain Microvessels -- ALP is a key enzyme of the 
blood brain barrier regulated by insulin. ALP may have a role in the 
metabolism of PLP, a cofactor of metabolic enzymes such as glutamate 
decarboxylase and glutamate transminase in the neural system. Brain ALP 
can significantly be inhibited by insulin (Catalan et. al., 1988). 
ALP in Liver — Although half of the circulating ALP in serum come from 
liver, no precise function of the LALP can be attributed since gross deficiency 
of liver ALP in congenital hypophosphatasia does not give rise to any obvious 
clinical manifestations. 
Bone formation 
The bone-specific ALP has an important role in skeletal mineralization 
(Anderson, 1989). BALP appears as tetrameric protein localized in the plasma 
membrane of the osteoblasts. Its activity is as 20 times higher in bone matrix 
vesicles, functionally active shed plasma membrane fragment ofthe osteoblast 
and the initial site of hydroxyapatite crystal formation. Robison (1923) first 
recognized the role of ALP in skeletal mineralization. 
BALP takes part in the bone mineralization processes by hydrolysing 
the organic phosphate esters resulting in local high Pi concentration which 
facilitates the precipitation of calcium phosphate. Moreover, ALP can destrjy 
the physiological crystal growth inhibitors such as inorganic pyrophosphate 
and ATP through its hydrolase activity. In addition, it acts as Pi transportor 
and actively transports Ca2+ or Pi through its ATPase activity (Whyte, 1994). 
Moreover, the extracellular matrix binding domain of BALP may be 
important in directing the migration of matrix vesicles along collagen fibers 
during the process of bone mineralization. 
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1.4 Normal Valiies of serum ALP 
In a health normal subject, the serum ALP level is mainly contributed 
by the bone and liver ALP isoform. The activity ofboth isoforms is marke<ily 
dependent on age (Fleischer et. aL, 1977; Leung, et al., 1993). The effect of 
bone growth, leading to an increase in BALP, and therefore to serum ALP, in 
children and adolescents is well established. After the growth spur, serum 
ALP drops dramatically, again due to the drops of BALP (Moss, 1982). On 
the contrary, LALP activity in serum increases steadily throughout life, and 
there is also some increases in BALP in the elderly (Figure 1.11). 
IALP activity rises following the ingestion of a fatty meal. The 
presence of intestinal ALP is more frequent in the serum of healthy 
individuals with blood groups B or 0 who are secretors (Langman et al., 
1966). As previously stated, placental ALP plays an important role in the 
pregnancy, it is therefore no surprise to see that PALP appears in serum of the 
pregnant mother. PALP is observable in matemal circulation after 5 to 6 
weeks of conception (Okamoto et al,, 1990). Placental ALP is also present in 
trace amounts in serum from healthy, non-pregnant individuals (Hendrix et. 
al., 1990). 
1.5 Clinical Applications ofALP 
The importance of the measurement of ALP activity in serum has not 
decreased during the half century since its introduction into diagnostic 
enzymology. Indeed, the growth of multiparameter biochemical profiling has 
consolidated its position amongst the most frequently performed tests in 
clinical chemistry. Main application of serum ALP level lies on the bone and 
hepatobiliary diseases (Moss, 1992). 
ALP measurement was first applied to investigate bone diseases on a 
theoretical basis established by Robison (1932) and Kay (1929), through their 
demonstration of the association between an elevated ALP activity in semm 
and increased osteoblastic activity. Elevated serum ALP activity occurs in 
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many skeletal disorders which reflects bone rebuilding processes increase in 
osteoblastic activity. This generalization remains the basis for the 
interpretation of serum ALP values in bone activity. 
The highest serum ALP levels are generally encountered in Paget's 
disease of bone and in broad terms the increase reflects the extent of the 
disease. The increase can be up to 25 fold of the normal values (Joplin & 
Steveson, 1990). Elevated serum ALP levels are also present in patients with 
osteomalacia and rickets. Malignancy of bone, especially osteosarcoma, can 
lead to elevations of serum ALP level which will be discussed with more 
details in the later section. In addition, during the healing process of the 
fracture, serum ALP level is increased with an increase in the osteoblastic 
activity. 
Later, the raise of serum level was proven also related to hepatobiliary 
disease (Roberts, 1930) in which the ALP levels are normal or only 
moderately elevated in hepatitis, but are markedly raised in obstructive 
jaundice. The large elevation of serum ALP is mainly caused by the LALP 
isoform. The obstruction to flow of bile results in regurgitation of bile 
constituents into the blood. Moreover, it also causes the de novo synthesis of 
ALP at the canailicular face of the hepatocyte and thus increasing the 
circulating ALP (Price, 1993). The ALP level always returns to normal after 
removal of the obstruction. 
A wide range of clinical conditions may also give rise to an increase in 
the serum ALP activity, such as rheumatoid arthritis, ankylosing spondylitis, 
renal disease. Pregnant women will show increase in ALP levels. However, 
the main clinical interest centers on the elevation of serum ALP in patients 
with diseases involving the liver or bone. The main clinical questions are 
concerned with: 
1. detecting the presence of liver or bone disease; 
2. determining the origin of an unexpected elevation ofserum ALP; 
3. monitoring the changes in the activity of the disease. 
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Thus, the major requirement is for methods that provide accurate and 
precise quantitation of different ALP isoforms, especially the bone and liver 
ALP isoforms. 
1.6 Separation, identification and quantification of ALP isozymes 
There are a wide ranges of techniques available for the characterization 
and quantitation of the multiple forms of ALP in serum. The techniques 
depend on the physicochemical properties, the nature of the catalytic site or 
protein structure and post-translation modification of the different isoforms. 
1.6.1 Thermostability 
Semiquantitation fractionation of different ALP isozymes can be 
achieved according to their thermostability (Patitclerc, 1976). The placental 
and germ-cell ALPs are remarkably thermostable. They may be heated at 
65°C for an hour or more without loss of activity (Neale et. aL, 1965). In 
contrast, the intestinal and the tissue-nonspecific ALP are rapidly inactivated 
under these conditions (Table 1.4) but the intestinal ALP is more thermostable 
than other tissue-nonspecific ALPs. LALP in semm is found to be slightly 
more thermostable than the BALP isoform (Whitby & Moss, 1975). 
1.6.2 Inhibition studies 
Various low molecular weight substrates show differential inhibition of 
the different ALPs (Harris, 1989). The effects of various kinds of inhibitors 
are listed in Table 1.5. All these inhibitors are stereospecific and ncn-
competitive. The placental, germ-cell and intestinal ALPs are about 30 times 
more sensitive to inhibition with L-phenylalanine than the tissue non-specific 
ALP. On the other hand, the tissue non-specific ALP are very much sensitive 
to L-homoarginine and levamisole inhibition than the tissue specific ALP. L-
leucine characteristically gives stronger inhibition with germ-cell ALP than 
with other ALPs and thus valuable for differentiating the placental and germ-
cell ALP. In addition, L-phenylalanyl-glycyl-glycine gives sharp differential 
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Human ALP 56�C(min)* 65�C(min)* 
Tissue Nonspecific ALP 7 4 ]_^ 
Mestinal ALP >60.0 一 6.5 
Placental and germ-cell ALP 二 >60.0 
Table 1.4. Relative thermostabilities of Human ALPs 
* Time in minutes required to give 50% inactivation of different human 
ALPs at 56°C and 65°C. 
Inhibitor L/K7B Intestinal Placental Germ Cell 
ALP* ALP* ALP^ ALP^ 
T^enylala i i ie 31 0.8 1.1 0.8 
T^omoarg in ine “ 2.7 40 >50 36 
L-Phenylalanyglycylglycine 3 0.6 ^ ^ 2.9 
L-leucine 13TT" 3.6 5.7 0.6 “ 
T ^ a m i s o l e 0.03 6.8 1.7 2.7 
Table 1.5 Effects ofvarious inhibitors on different Human ALPs 
* Concentrations (mM) of various inhibitors required to produce 50% 
inhibition of different liiiman ALPs under standardized conditions. 
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inhibition between placental, intestinal and tissue-nonspecific ALP. This 
property also aids the differentiation between the placental and germ-cell ALP 
as inhibition pattem of germ cell ALP is more similar to the intestinal ALP. 
1.6.3 Electrophoresis 
The most common approach for identification of ALPs depends on 
electrophoretic separation, followed by staining for enzymatic activity (usually 
with a-naphthyl phosphatase as substrate and with diazonium salt to detect the 
liberated a-naphthol). However, zonal electrophorsis alone, no matter on 
which support media, fail to produce a distinct separation of the most 
important isoforms, namely liver and bone ALP isoform and allow accurate 
quantitation (Moss, 1982). 
In case of paper (Baker & Pellegrino, 1954), starch (Jennings et aL, 
1970) and cellulose acetate supports (Siede & Seiffert，1977)，the main liver 
isoform migrates as a compact band in the a2 globulin region. The bone 
isoform is found to be immediately behind the liver bands and is characterizc;d 
by more diffuse staining. Even with the molecular sieving supports such as 
agarose (Hagerstrand & Skude, 1976) and polyacrylamide (Walker & Pollard, 
1971) support, the close proximity of the liver and bone fractions will still be 
seen. 
The adult intestinal isozyme exhibits a slower mobility than the liver 
and bone ALP in the case of all supports. The placental ALP shows a more 
microheterogeneity in starch and polyacrylamide gel electrophoresis system 
(Robson & Harris，1967) and appears as a discrete band overlaying the diffuse 
bone fraction. 
The electrophoretic mobility of the bone isoform may be retarded by 
pre-incubation with neuraminidase (Moss Sc Edwards, 1984) or wheat germ 
lectin (Rosalki & Foo, 1984). This allows the quantitation of both the bone 
and liver fractions even when only small amounts of one component was 
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present. Both of these procedures depend on differences in the sialic acid 
residues of liver and bone ALP. 
1.6.4 Isoelectric Focusing 
It is possible to improve the resolution of electrophoretic techniques by 
employing isoelectric focusing (IEF). IEF is an electrophoretic technique in 
which amphoteric compounds are fractionated according to their isoelectric 
points (pIs) along a continuous pH gradient. Different ALP isozymes, since 
having different amino acid sequence, have different pI and thus can be 
separated from each others (Westermeier, 1993). For tissue nonspecific ALP 
isoform such as LALP and BALP, although the protein moieties are the same, 
the difference in the degree glycoslyation, especially the sialic acid content, 
will influence the net charge of the molecule, thus providing a means for 
separation. 
By means of IEF technique, it was possible to separate ALP into at 
least 10 to 20 distinct bands (Griffiths & Black, 1987; Rosendahl et. aL, 
1987). Unfortunately, the large number of bands appears to confuse. It is 
difficult to clarify the position of the clinically significant ALPs. However, it 
is usefUl for the characterization and identification of unusual ALP variants. 
1.6.5 Affinity precipitation 
Rosalki and Foo (1984) first reported that Wheat germ lectin (WGL) 
can preferably (80%) bind to the bone ALP isoform than the liver isoform and 
thus differentiating the bone fraction from liver fraction from serum. WGL 
binds to both N-acetylglucosamine and sialic acid residues and relative 
affinities for individual proteins will depend on the relative amount and 
accessibility of either or both of these sugars. 
The same groups (Rosalki & Foo，1986) later pointed out that the 
biliary fractions had to be dissociated by treatment with Triton X-100 to avoid 
the co-precipitation of this portion. Several commercial developed kits of 
BALP measurement (IsoALP, Boehringer Mannheim) are using this WGL 
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binding properties. However, some authors pointed out the reproducible of 
the assay is affected by quality of the WGL (Behr & Barnert，1986; Desoize, 
et. al., 1986). 
1.6.6 Immunological studies 
The first antibody against ALP was raised in 1954 with specificity 
towards dog intestinal ALP (Schlamowitz, 1956). The intestinal and placental 
ALP show some structural similarities and early polyclonal antisera 
demonstrated large cross reactivity (Lehmann, 1975). The achievement of 
specificity has only been successfully accomplished with the selection of 
monoclonal antibodies. Monoclonal antibodies against even different allelic 
forms of placental ALP can be achieved (Slaughter et. al., 1983). Monocloaal 
antibodies for intestinal ALP without cross reactivity were also produced 
(Bailyes et al., 1988). 
Several groups have attempted to differentiate between liver and bone 
isoforms using monoclonal antibodies but all antibodies raised show certain 
degree of cross reactivity due to the close structural similarity between the 
isoforms. Recent report of Hill and Wolfert (1989) demonstrates the 
production of monoclonal antibody against human bone ALP isoform with 
only 3% cross reactivity with the liver isoform, using BALP from human 
osteosarcoma cell line (Sa OS-2) as immunogen. Commercial ELISA kit 
(ALKPHASE-B®，Metra Biosystem) using monoclonal antibodies against 
BALP is now available for the direct capture and measurement of BALP in 
serum. The epitope of the monoclonal antibody recognizes the molecular 
conformation rather than the portion near sialic acid linkages in ALP 
molecules (Hata, et. al., 1996). 
1.7 Plasma BALP level as biochemical marker of Osteosarcoma 
It is known that many patients with osteosarcoma have high serum total 




Bacci (1993) and his colleagues examined the serum ALP level of 656 
patients with serum osteosarcoma and concluded that the pretreatment serum 
ALP levels have a prognostic value. His group demonstrated that die 
percentage of patients with increased serum ALP was significantly higher in 
the metastatic group than in the group with localized disease. Moreover, the 
relapse rate was significantly higher in patients with elevated ALP level than 
in normal level. 
The reduction of elevated plasma ALP levels following the 
chemotherapy is a valuable guide to administration of chemotherapy. Rosen 
et al (1974) demonstrated the effect of neoadjuvant chemotherapy on serum 
ALP values in a patient with proximal humeral osteogenic sarcoma. The 
decline of elevated values to normal levels signifies the sarcoma is responding 
favorably to chemotherapy. 
Despite of the successfulness of these demonstrations, application of 
serum total ALP in bone diseases still lacks its specificity and sensitivity. As 
stated in the previous section, serum ALP is contributed not only by bone but 
also from liver origin, raise in serum ALP level is therefore not restricted in 
bone disease. As a cancer marker of bone tumor, elevated total serum ALP 
provides no indication about the site of metastases and its relationship to 
skeletal activity cannot be established without quantifying the amount of 
serum bone isozyme (Leung, et al, 1993; Burlina, et al., 1994). 
It is therefore much more reasonable to use plasma BALP as a more 
specific indicator for osteosarcoma since it will avoid many complications 
which will lead to the raise of other forms of ALP, especially liver damage 
induced by the chemotherapeutic agents (Breithaupt 8c Kuenzlen，1983j. 
Moreover, BALP is a more sensitive biochemical marker of bone activity ?.nd 
its level truly reflects the bone activity (Liu et al, 1996) 
The application of plasma BALP measurement, in the past, is primary 
limited by the methods of measurement. Separation of plasma BALP from 
LALP can only be achieved by electrophoresis, which is too expensive and 
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cumbersome for routine measurement in clinical laboratory. Heat inactivation 
only allows semiquantitative measurement of plasma BALP. Accurate, easy 
to perform and less expensive methods for routine assay of plasma BALP 
level is only possible after the introduction of wheat germ lectin precipitation 
assay by Rosalki and Foo (1984). However, wheat germ lectin precipitatbn 
assay will yields falsely high values in patients with hepatobiliary diseases 
because of coprecipitation of the liver isoform (Withold & Rick, 1994) and 
BALP is not precipitated with similar efficiency in different sera (Farley et al., 
1993). 
Recently, another accurate measurement of plasma BALP was 
introduced using the monoclonal antibody against human plasma BALP (Hata 
et al., 1996). This ELISA (ALKPHASE-B®) captures the BALP in the 
plasma sample by the monoclonal antibody, coated in the bottom of the assay 
well, the BALP activity is then directly measured by using p-nitrophenyl 
phosphate as substrate. 
1.8 ALP in malignancies 
Numerous associations have been reported between the expression of 
tissue specific ALPs and malignancy (Herz, 1985). Tumors which express 
these ALP isozymes can be broadly divided into two groups: (1) those with an 
enhanced production of an isozyme normally expressed in the tissue (eutopic 
expression) and (2) those showing expression of one or more isozymes not 
identified in the normal tissue (ectopic expression). Moreover, many tumors 
show simultaneous expression of two or more different ALP isozymes 
CNozawa etal., 1990; Millan, 1992). 
Placental ALP was one of the first enzyme recognized as an oncofetal 
protein by Fishman et al. (1968) in a patient (Regan) with disseminated lung 
cancer. It was termed Regan isozyme at that time and its functional 
characteristics were indistinguishable from those of the placental ALP 
biochemically, immunologically and structurally (Greene & Sussman，1973). 
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The "Regan" isozyme has been reported in malignancies of lung, 
gastrointestinal tract, ovary, uterus, and in other tissues (Fishman et. al, 
1976). However, only some of the patients with these malignancies produce 
the enzyme. 
Two years later, the Nagao isozyme was also found in cancer patients 
(Nakayama et. al, 1970). This isozyme differs from PALP by its slower 
migration on starch gel and its sensitivity to leucine inhibition and it is most 
frequently expressed in germ cell tumor and ovarian cancer and actuaUy 
serves as an useful tumor marker in those tumors. We now know that this 
Nagao isozyme expression are the results of eutopic expression of the Germ-
cell ALP gene (Horfmann 8c Millan, 1993). Germ cell ALP is also ectopically 
expressed in tumors like pineal gland and thymus but only with low incidence 
of expression. 
In 1972, Higashino and co-workers reported the presence of an 
intestinal-like ALP variant in patients with hepatocellular carcinoma and 
named this variant Kasahara isozyme after the first patient's name. By use of 
specific monoclonal antibodies, studies (Moss et al., 1986; Imanishi et al., 
1989) shown that this isozyme is a heterodimer ofPALP and IALP monomers 
which are similar to the fetal form of intestinal ALP. IALP appears to be 
primarily expressed in hepatomas although it has been found in other tum )rs 
as well. 
Several different mechanisms underlying ALP expression in tumor 
cells can be envisioned (Millan & Fishman, 1995): 
1. A functional involvement ofALP isozymes in tiimorgensis; 
2. ALP expression may represent an factor in a multifactorial etiology; 
3. ALP expression may represent a close linkage of the ALP gene with a 
disease susceptibility gene; 




5. The expression of ALP isozyme genes could be the result of random 
chromosomal aberrations. 
In osteosarcoma, eutopic expression of the bone-specific ALP is found. 
In 1993，Stinson and his group investigated the ALP gene expression in six 
human osteosarcoma cell lines in order to explore the possible molecular 
mechanisms for differences in specific activity of ALP. In six of the human 
osteosarcoma cell lines chosen, five of them express detectable levels of only 
the B/L/K ALP mRNA. However, in one of the cell lines which had the 
lowest expression of ALP mRNA (U-2 OS), they found a mixture of tissue-
nonspecific ALP mRNA and at least one other form which indicated that an 
ectopic expression of ALP may be also present in osteosarcoma. 
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Aim of study 
Increased level of serum alkaline phosphatase has long been used by 
other researchers as a biochemical marker in osteosarcoma. In the present 
project, we plan to test the possibility of using the bone-specific alkaline 
phosphatase as a more specific and sensitive plasma biochemical marker for 
diagnostic and prognostic purposes. 
In the quantitative studies, plasma bone-specific ALP in osteosarcoma 
patients throughout the treatment periods were measured. Both wheat-germ 
lectin precipitation assay and the ALKPHASE-B immunoabsorption assay 
were employed for the measurements. The normal reference value of local 
Chinese population was determined. Comparison between the plasma BALP 
level of the patients at the time of diagnosis with the normal reference will 
provide useful information about the diagnostic and prognostic value of 
plasma BALP values. In addition, in order to evaluate the usefulness of plasma 
BALP level in monitoring the treatment progress, the change of plasma BALP 
level of the patients during the whole treatment plans up to the time of 
recurrence (if any) were followed. 
In attempt to search for an even more specific biochemical marker for 
osteosarcoma, in the second part of the present project, we investigated the 
probable existence of the ectopic expression of ALP in osteosarcoma. Stinson 
(1993) reported the expression of ALP mRNA which is not originated from 
liver/kidney/bone in human osteosarcoma cell line U-2 OS. We explored the 
nature of this ectopic expression in this osteosarcoma cell line using ihe 
biochemical, isoelectric focusing and immunohistochemistry technique, and 
another human osteosarcoma cell lines (Sa OS-2) was employed as control. 
Furthermore, in order to screen for any ectopic expression of ALP in our 
clinical cases, we partially purified and identified the ALP expressed in 
X 
osteosarcoma patients' plasma samples and tumor tissues. In addition, 
immunohistochemistry using monoclonal antibody against human placentJ 
ALP were also applied to our osteosarcoma tissue paraffin section obtained. 
xi 
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2. Methods and Materials 
2.1 Plasma BALP measurement as a biochemical marker in 
Osteosarcoma 
The plasma levels of BALP would be determined in normal Chinese 
and patients with primary osteosarcoma. These studies were in collaboration 
with the researchers of the Department of Orthopedics and Tramatology, the 
Chinese University ofHong Kong. 
2.1.1 Patient groups 
2.1.1.a Normal Subjects 
A total of 137 normal subjects of local Chinese population (age 9-86) 
including 82 males and 55 females were recruited. These normal subjects 
have no past history or present signs and symptoms of liver or metabolic bone 
diseases. All subjects were divided into different age groups with group N1: 
age below 12; group N2: age between 12 to 16; and group N3: age above 16. 
2.1.1.b Osteosarcoma Patients 
A total of 49 patients (age 9 to 61) with 32 males and 17 females 
diagnosd as primary osteosarcoma were recruited for study. Consent from the 
patients (or patients' parents if he/she is belovv 16) were made. In general, 
patients received neo-adjuvant chemotherapy before operational remove ofthe 
tumor then follow by adjuvant chemotherapy. Serial blood samples of the 
patients were taken at admission, during the pre-operative chemotherapy, day 
before and after the operation, during the post-operative chemotherapy and at 
every follow-up clinic after the chemotherapy. 
2.1.2 Collection and preparation ofpatient bloods samples ofpatients 
Subjects' arm was placed in extend position. Cephalic or Median 
Cubital vein was located. The arm was timaqiiited and the puncture site was 
sterilized with alcohol swap (BRAND). Venepuntiire was performed and 4 ml 
venous blood were aspirated with a 5 ml sterile syringe (TERUMO). The 
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tunaquit was unfastened and the syringe was withdrawn. The needle was 
removed and the blood was transferred immediately into a 4 ml heparinized 
tube with ammonium heparin coated on the wall of the tube (SARSTEDT). 
The tube was mixed gently for several times. Plasma sample was obtained by 
centrifogation at 1000 xg for 10 minutes within 1 hour after blood collection. 
Plasma was aliquoted into 0.5 ml Eppenddorfs and stored at -70°C 
immediately. 
2.1.3 Plasma Total ALP measurement 
Measurement of the plasma TALP is based on a modification from the 
suggestions from the International Federation of Clinical Chemistry (IFCC) 
methods for Alkaline Phosphatase. (Tietz et. al., 1983). The simplified 
equation for the reaction is shown in Figure 2.1. Appearance of the highly 
yellow colored products, p-nitrophenol, is monitored continuously at 405 nm 
at 25°C as the alkaline phosphatase in plasma catalyzed the hydrolysis of the 
colourless substrate, p-nitrophenylphosphate. The reaction takes places at a 
rigorously controlled pH 10.30 maintained by the transphosphorylating buffer, 
2-amino-2-methyl-1 -propanol. The rate of increase in yellow color is directly 
proportional to the ALP activity in the sample. One unit of activity is defined 
as that amount of enzyme which produce 1 ^iniole of p-nitrophenol per minute 
under the conditions of the assay procedure. 
2.1.3.a Reagent 
2-Amino-2-methyl-l-propanol (AMP) Buffer (0.5M, pH 10.3) 
2-amino-2-methyl-1 -propanol (Sigma) was warmed at 37�C water bath until it 
liquidified. 4.79 ml of this solution was added slowly in approximate 60 mi of 
deionized distilled water (ddH2O). 0.04066g of MgCl2 . 2H2O (Sigma) was 
added to give a final concentration o f 2 mM. The buffer is titrated with lM 
















































































































p-Nitrophenyl phosphate (pNPP) Substrate Solution 
pNPP substrate was prepared one hour before used. Every tablet of Sigma 
Diagnostics 104® phosphatase substrate tablet (40 mg of pNPP per tablet) was 
dissolved in 5 ml of the AMP buffer to give a final concentration of 8 mg/ml. 
It was allowed to stand for 1 hour and shade vigorously before use. 
2.1.3.b Procedure 
Plasma samples stored at -70°C were thawed and kept at room 
temperature. 20^il of each test samples were pipetted into 96 well platjs. 
Reaction was started by adding 250^il of substrate solution and the change of 
absorbance at 405 nm were continuously monitored at 1 min interval with 
Dynatech MR5000 Microplate reader. All measurements were preformed in 
triplicate. 
Standard curve of the production of p-nitrophenol (pNp) was 
constructed using p-nitrophenol standard solution (Sigma Diagnostics 104®, 
10 p,mol/ml). Serial dilution of 4^mol of pNp standard solution were made by 
AMP buffer and diluted to 270 \A volume. Absorbance was measured at 405 
nm and standard curve was constructed by plotting the amount of p-
nitrophenol (^imol) against the absorbance. Amount of pNp formation by the 
test samples was determined from the standard curve and activity is calculated. 
2.1.4 Plasma Bone ALP measurements 
Thoughtout the study periods, 3 methods were employed for the plasma 
bone specific ALP activity measurement. Two methods were based on the 
Wheat-germ Lectin specific binding of the BALP but using different buffer 
and autoanalysor system. Methods adopted in Orthopedics and Tramatology 
Department previous using ABBOTT VP system and A-gent® Alkaline 
Phosphatase reagents (ABBOTT Method) while samples measured by the 
Chemical Pathology Department are using MIRA COBAS system with 
ROCHE ALP IFCC reagent (MIRA COBAS Method). 
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The wheat germ lectin (WGL) binding assay for BALP measurement 
was described by Rosalki and Foo (1984). The original method required two-
step incubation with a pre-treatment of Triton X-100 provided that semm 
sample demonstrated the presence of biliary ALP. The pre-incubation was 
time-consuming and would complicate the calculation of bone-specific ALP 
activity. The original authors subsequently modified their method so that only 
one step incubation would be necessary for the precipitation ofBALP (Rosalki 
and Foo, 1986). The modified method was adopted in both departments. 
Another newly adopted method in Orthopedic and Tramatology Department is 
ALKPHASE-B™ (Metra Biosystems) which is an immoiiassay in microplate 
strips format utilizing a monoclonal anti-BALP antibody coated on the strip to 
capture BALP in the plasma sample. The enzyme activity of the captu:ed 
BALP is detected with a pNPP substrate. 
2.1.4.a Wheat Germ Lectin Precipitation of BALP 
2.1.4.a.i Reagent 
WGL/Triton X-100 Mixture 
0.0275 g ofWGL from Triticum vulgaris (Sigma) and 0.22g of Triton 
X-100 (Sigma) were dissolved in 5.5 ml ddH2O to give a final concentration 
of 5gyL WGL and 40g/L Triton X-100 working solution. The solution was 
mixed on a roller plate for at least 30 minutes until total dissolution ofWGL. 
2.1.4.a.ii Procedure 
Plasma samples stored at -70°C were thawed at room temperature. 
Precipitation of BALP was achieved by mixing 50 t^l plasma samples with 
equal volume of WGL/Triton X-100 solution. The mixtures were incubated at 
37°C with continuous shaking for 30 minutes. After incubation, the mixtures 
were centrifuged at 2000 xg for 10 minutes at 4°C. Supernatant was taken for 
the estimation of non-bone ALP activity. 
44 
r i^nl6rinlc- : MRlh.Grlf3 
2.1.4.b ABBOTT Methods for plasma BALP activity measurement 
ALP activity of the untreated plasma and the supernatant were 
measured by using ABA-100® procedure of the ABBOTT VP system. 50ul 
ofthe water blank, the controls and the test sample were pipetted to the sample 
cup of the ABBOTT VP system. The machine setting was as follow: 
Filters 450/415 
Syringe Ratio 1:101 
Analysis Time 5 min. 
Carousel Revolutions 3 
Temperature 37°C 
End-point or Rate RATE 
Reaction Direction Down 
Calibration Factor ——工^湖—— 
FilterFactor 
Zero-adjustment 1800 
Using the above instrument settings, syringe plate was filled with A-
Gent Alkaline Phosphatase reagent. The probe was positioned in the 
reservoir, Manual Dispense Switch was used to recycle the reagent through the 
syringe plate, and then the probe was attached to the end of the boom arm. 
The program was then run, and ALP activity of the samples were 
automatically calculated by the analyzer. 
BALP activity was calculated from the difference between the total 
ALP in the untreated sample and the supematant collected after WGL 
precipitation as shown below: 
Bone-specific ALP (U/L) = Total ALP (VfL) - 2 x Non-Bone ALP (U/L) 
2.1.4.c COBAS MIRA Methods for BALP measurement 
50^il of water blank, controls and each measured sample were pipetted 
into the sample vial of the COBAS MIRA system. All vials placed into the 
sample rack, curette ring was installed into the machine and reagent chamber 
45 
\/'>r^eT\n\r, fl. R(r::T|-ir;rl[-
was filled with ROCHE ALP IFCC reagent. The machine was then run as the 
following parameter: 
GENERAL 
Measurement Mode ABSORB 
Reaction Mode R-S 
Calibration Mode FACTOR 
Reagent Blank REAG/DIL 
Cleaner NO 
Wavelength 405 nm 
Unit U/L 
ANALYSIS 
Post Dil. Factor NO 
Post Conc. Factor NO 
Sample Volume 6.0 p,l 
Diluent Name H20 
Volume 50.0^il 
Reagent Volume 250 i^l 
Reac. Direction Increase 
Low Test Range NO 
High Test Range 1300U/L 
Factor 4607 
BALP activity of the samples was calculated as in ABBOTT Methods. 
Control sera from human (TALP activity: High control 319-387U/L; Low 
control 75-91) were included in each run. 
2.1.4.d ALKPHASE-B Method ofBALP measurement 
Desired number of Anti-BALP Coated Strips were placed in the 
Stripwell frame and 125 i^l Assay Buffer was added to each well. Then 20^il 
of Standard, Control or sample were pipetted to each well within 30 minutes. 
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The strips were swirled gently to ensure mixing of sample and buffer. The 
plate was then incubated at room temperature for 3 hours. 
The wash buffer concentrate was diluted 10 times with deionized 
distilled water. Working substrate solution was prepared within one hour of 
use by adding each tablet (20 mg of pNPP) into 10 ml of substrate buffer. 
Mixture was allowed to stand for 30 - 60 minutes and then shaken vigorously 
before use. 
After the incubation, the strips was emptied and each well was washed 
with at least 250^il working wash buffer for a total of 4 times. The strips were 
vigorously blotted dry after the last wash. Then 150f_il Working substrate 
solution was added into each well and incubated for 30 min. at room 
temperature. The reaction was then stop by adding 100^1 of lM NaOH, the 
absorbance of the plate was read at 405 nm by Dynatech MR5000 Microplate 
reader. All readings were made within 15 minutes after stopping the reaction. 
Standard curve was constructed by the BALP standards (0, 2, 20, 50, 
80, 140 U/L) and the BALP activity of the samples was calculated from the 
standard curve. Controls were included in each run (BALP activity: High 
Control with 55.4-84.0 U/L; Low Control with 11.1 -16.9 U/L). 
2.1.5 Inter-conversion of plasma BALP activity measurement in 
different methods. 
In order to compare the results obtained by different methcds, 
correlation between different methods of BALP activity measurement was 
constructed. Conversion factor between the ALKPHASE-B method and the 
COBAS MIRA method was calculated by measuring the BALP activity in 58 
plasma samples obtained from the Chemical Pathology Department with both 
methods. Conversion factor between ALKPHASE-B method and the 
ABBOTT methods was calculated by measuring 67 plasma samples of our 
patients with both methods. All BALP activity was expressed in unit 
compatible to the ALKPHASE-B method. 
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2.1.6 Statistical Analysis 
One Way ANOVA, Student's T-test of independent samples were 
employed for comparison between groups with 2-tailed significance of 0.05. 
Data were presented using Boxplot. Correlations between groups are 
investigated by bivariate correlation model with Pearson correlation 
coefficients and with 2 tailed significance of0.05. 
ANOVA is an statistical analysis used to determine whether means 
from two or more samples are drawn from populations with the same mean. 
For the One-way ANOVA, the groups are defined on only one independent 
variable. In our analysis, One-way ANOVA is used when the means of more 
than 2 groups are compared. 
The normal reference value of the plasma BALP in local Chinese 
population is determined according to the recommandation of IFCC and 
International Committee for standardization in Haematology (ICSH). 
(Solgery, 1987). For age group N1 and N2, normal references was determined 
by the range of BALP measurement in these subjects. For group N3, non-
parametric method was used to determine the lower (0.025 fractile) and upper 
range (0.975 fractile) of the reference, which contains the central 0.95 fraction 
of the reference distribution 
All analyses were made by SPSS for Windows (Version 6.0) in PC. 
2.2 Alkaline Phosphatase Isozymes Expression in Human Osteosarcoma 
2.2.1 In Vitro Cultures ofHiiman SaOS-2 and U-2 OS Osteosarcoma ceJl 
line 
Human SaOS-2 and U-2 OS Osteosarcoma cell lines were purchased 




Phosphate Buffer Saline (PBS) 
PBS was prepared by dissolving 8.0 g ofNaCl, 0.2 g KC1, 1.15 g cf 
Na2HPO4 and 0.2 g of KH2PO4 in lL double distilled water. The solution 
was sterilized by autoclaving at 121°C, 15 psi for 30 min. 
Dulbecco's Modified Eagle's Medium (DMEM) 
DuIbecco's Modified Eagle's Medium powder was purchased from 
Sigma. The powder was dissolved in 1 liter of double-distilled water, and the 
solution was supplemented with 3.7 g ofNaHCO3 and adjusted to pH 7.2-7.4. 
Sterilization was done by filtering through 0.22 ^m Millipore HV filter, with 
the addition of 1 % (v/v) penicillin-streptomycin. (Gibco) 
Fetal CalfSerum (FCS) 
FCS was purchased from Gibco and was stored at -20°C in 10 ml 
aliquot until use. 
Trypsin/EDTA Solution 
Trypsin/EDTA solution was purchased from Gibco. The solution 
contains 0.25% trypsin and 0.53 mM EDTA (ethylenediamine tetraacetic acid, 
tetrasodium salt) in Hank's Balance Salt Solution (HBSS) without Ca^+ and 
Mg2+. 
Glutamine Stock Solution 
200 nM Glutamine stock was prepared by dissolving 0.2922g of L-
glutamine into 10 ml ofDMEM. The solution was then sterilized by filtering 
through a 0.22 i^m membrane. 
Standard Medium 
Standard medium referred to the medium supplemented with fetal calf 
serum, antibiotics and L-glutamine. Ten ml ofFCS and 1 ml of L-glutamine 
stock were added into 89 ml DMEM containing 1% PSN. 
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Trypan Blue Exclusion test 
Trypan blue (Sigma) was dissolved in PBS at a final concentration of 
0.1% (w/v) and filtered. An aliquot of cell suspension (lOp,l) was mixed with 
an equal volume of trypan blue solution. After mixing, the unstained viable 
cells were counted by a haemocytometer. 
2.2.1.b Procedure 
2.2.1.b.i Storage ofU-2 OS ancl SaOS-2 
Upon receiving from the suppliers, both cell lines, the U-2 OS (ATCC 
HTB-96) and SaOS-2 (ATCC HTB-85) were thawed at 37°C within 1 minute. 
The cells were aspeptically transferred to 10 ml of Standard medium and 
centrifLiged immediately at 1300 x g for 5 minutes. The cell pellet was 
washed with PBS three times. Finally, the pellet was resiispended in standard 
medium, seeded inside a 75 cm^ culture flask (Corning) and incubated at 37°C 
(5% CO2 ； 95% Humidity) for overnight. The adherent cells were subcultured 
when confluent. Part of the cells was taken for cell line maintenance. Cell 
line was kept at the concentration of 1 x 10^ cells/ml in 10% DMSO 
(Dimethylsulfoxide, Sigma) in standard medium. The cell suspension was 
frozen stepwisely to -70°C and then stored in liquid nitrogen. 
2.2.1.b.ii Subculture ofConfliient Monolayer 
Confluent monolayer of cells was rinsed twice with PBS. 
Trypsin/ETDA solution (1 ml for 75 cm^ flask, 0.5 ml for 25 cm^ flask) was 
added to the monolayer and the culture flask was incubated at 37°C for 3 
minutes. To stop the trypsinization, 5 ml of standard medium was added. The 
cells were dispersed by repetitive pipette against the monolayer. The released 
cells were aspirated out. The flask was rinsed with the standard medium and 
pooled to the released cells. The cells were pelleted at 1500 xg for 10 minutes 
and the pellet was washed by plain medium. Finally cells were resuspended in 
standard medium and viable cell number was counted under hemocytometer 
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by trypan blue exclusion test. SaOS-2 cell line was maintained by seeding 0.5 
X 106 cells and U-2 OS cell line by seeding 0.3 x 10^ cells to 25 cm^ flask. 
2.2.2 Protein Assay 
Protein concentration was measured by the Bio-Rad Protein Assay 
based on the method of Bradford. Microtiter plate protocols of both the 
standard assay and microassay were adopted. ‘ 
2.2.2.a Standard Assay 
2.2.2.a.i Reagent 
Protein standard for standard assay 
Protein standards were prepared with bovine serum albumin (BSA) 
(Sigma) dissolving in double distilled water to obtain protein concentration 
range from 0.05 mg/ml to 0.5 mg/ml. 
Diluted dye reagent for standard assay 
Protein Assay Dye Reagent Concentrate (Bio-Rad) was diluted 4 fold 
with double distilled water and filtered through Whatman # 1 filter to remove 
particulate. 
2.2.2.a.ii Procedure 
Ten p.1 of each standard and sample solution was pipetted into separate 
microtiter plate wells and 200^il diluted dye reagent was added to each well. 
The samples and reagent were mixed thoroughly and incubated at room 
temperature for at least 5 minutes before reading absorbance at 595 iim. 
2.2.2.b Microassay 
2.2.2.b.i Reagent 
2.2.2.b.ii Protein standard for Microassay 
Protein standards were prepared with BSA by dissolving in double 




160p,l of each standard and samples solution were pipetted into separute 
wells and 40^il of dye reagent concentrate was added into the wells. The 
samples and the dye were mixed and incubated at room temperature for 5 
minutes. Aborbance was measured at 595 nm. 
2.2.3 Extraction of ALP from the cultured osteosarcoma cells 
The method of extraction of the membrane bound ALP from the 
cultured cell were modified from the original methods described by Nakamura 
et a/.(1988) and Belland et al. (1993). 
2.2.3.a Reagents 
Cell Washing Buffer (pH 7.6) 
Cell washing buffer contains 10 mM of Tris-HCl, 1 mM of 
MgCl2.6H2O, 0.1 mM 0fZnCl2 and 150 mM ofNaCl. Solution was prepared 
in double distilled water and titrated with lM NaOH to pH 7.6 at room 
temperature. 
ALP Extraction Buffer (pH 7.6) 
The ALP extraction buffer contains 100 mM Tris-HCl, O.lmM of 
MgCl2 6H2O, 0.02 mM of ZnCl2, and 1% Triton X-100 (w/v). Buffer was 
prepared with double distilled water and pH adjusted by lM NaOH to pH 7.6 
at room temperature. 
2.2.3.b Procedure 
Solubilization of ALP 
Confluent SaOS-2 cells and U-2 OS cell adherent to the walls of the 
flask were removed with the help of a rubber policeman. The cells were 
washed by 2 ml washing buffer and centrifuged at 1500 xg for 5 mins. The 
supernatant was discarded and the pellet washed twice with the buffer. The 
pelleted cells were then resuspended in 1 ml of the extraction buffer. The 
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resuspension was then undergo a freeze and thaw cycle and then sonicated ibr 
1 minute at a constant low setting using a Beckman Sonic 2000 sonicator on 
ice. The mixture was rocked gently at 4°C for 90 minutes and the protease 
inhibitors: leupeptin (5|imol/L), pepstatin A (25^imol/L) and PMSF (0.01%, 
w/v) were added. 
Phosphatidylinositol phospholipase C (PI-PLC) release ofALP 
1 Unit of PI-PLC enzyme (Boehringer) with specific activity of 
20U/332p,l was added to every ml of the cell lysate. The mixture was 
incubated at 37°C with continuous shaking for 20 hours, followed by 
centrifliged at 14,000 xg using Beckman Optima TLX Ultracentrifuge for 10 
min. at 4°C. The supernatant was collected and the ALP activity of tbe 
released enzyme preparation was measured. 
2.2.4 ALP extraction from Human Liver, Placenta and Osteosarcoma 
Tissue 
Membrane preparations from the human tissues were prepared by a 




0.9 g ofNaCl was dissolved in 100 ml ofdouble distilled water. 
Homogenate Buffer 
Homogenate buffer contains 250mM sucrose, 5mM MgCl2, 24rrM 
KC1 and 50mM Tris-HCl. Buffer was prepared using double distilled water 
and the pH was adjusted by using 1 M NaOH to pH 7.5. Buffer was kept at 
4 � C until use. 
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2.2.4.b Procedure 
Tissue Preparation 
Placenta: Full-term human placenta was obtained from the Department of 
Obstetrics and Gynaecology. Weight ofthe tissue was recorded and the tissue 
was cut into several pieces with mass approximately 10g per piece. The tissue 
was washed with saline to remove blood. It was deep frozen in liquid nitrogen . 
and then kept at -70°C until use. 
Liver: Human liver was obtained from the post-mortom room within 48 
hours of death. After washing with saline, the tissue was cut into small pieces 
with weight approximately 30 g and was immediately frozen in liquid nitrogen 
and then kept at -70°C until use. 
Osteosarcoma tissue: Human osteosarcoma tissue was obtained during 
the biopsy ofthe patients. The tissue was weighted and recorded. It was then 
frozen in liquid nitrogen and kept at -70°C until use. 
Membrane Preparation 
Human tissue of various sources were thawed at 4°C overnight, and 
then chopped into small pieces. The tissue was suspended in equal volume (1 
ml / g of tissue) of homogenate buffer. For human osteosarcoma biopsy 
tissue, since the amount of tissue was small, the tissue was resuspended in 5 
ml of buffer. The tissue was homogenized with Polytron (Kinematica®) at 
full speed on ice for 1 minute. The homogenate was centrifUged at 6000 xg 
for 10 minute. The supernatant was collected and filtered through two layers 
of Miracloth. The filtrate was re-centrifuged at 150,000 xg for 40 minutes at 
4°C. Supernatant was discarded and the pellet was washed with the 
homogenate buffer (0.3 ml / g of tissue in placenta and liver tissue, 5 ml for 
osteosarcoma biopsy tissue) and re-centrifuged at 150,000 xg for another 40 
min. at 4°C. The pellet was resuspended with the ALP extraction buffer 
without Triton X-100. Protein inhibitor leiipeptin (5^mol/L), pepstatin A 
(25^imol/L) and PMSF (0.01%, w/v) were added. Both the ALP activity and 
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the protein concentration were measured. The crude particulate was stored at -
20°C until use. 
PI-PLC release ofALP from the crude particulate 
Except for the human osteosarcoma biopsy tissue, the crude particulate 
of human liver and placenta were diluted with the ALP extraction buffer to 
give a final concentration of 2 jig of protein/ml. Triton X-100 was added to 
give a final concentration of 1% (w/v). ALP was then released from the 
membrane preparation as the method described at section 2.2.3.2. 
2.2.5 Isoelectric Focusing of ALP 
IEF is an electrophoretic technique in which amphoteric compounds are 
fractionated according to their isoelectric points (pIs) along a continuous pH 
gradient. The pH gradient is created and maintained by passing an electric 
current through a solution of amphoteric compound (carrier ampholyte) which 
have closely spaced pIs, encompassing a given pH range. Agarose IEF is 
especially suitable for the separation of ALP isozymes since ALP of different 
origins, although have the same or similar protein sequence, are differ from 
their carbohydrate moieties (Miura et aL, 1994). The difference in their sugar 
or the nucleic acid composition in the moieties will have influence on the net 
charge of the protein, providing an addition force for the separation compared 
to the ordinary zonal electrophoresis. 
2.2.5.a Preparation oftlie agarose IEF gel 
Agarose gels were casted on GelBond® film for agarose gel 
(Pharmacia Biotech). The GelBond was cut into a 12 x 12 cm square. It was 
then placed on a leveling table with a film of70% ethanol with the hydrophilic 
surface up onto the level table. The leveling table was kept horizontal by 
using a spirit level and the GelBond film was pre-warmed using a hair-dryer. 
The 1% agarose gel solution was prepared by dissolving 0.15 g agarose 
IEF (Pharmacia Biotech), 1.8 g sorbitol (Sigma, Electrophorsis Grade), 1.7"5 
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ml glycerol (Pharmacia plusone chemicals, 87% w/v) in 10 ml deionized 
distilled water in 100-ml conical flask. The solution was warm by boiling 
water bath until the agarose was dissolved completely. Meanwhile, 0.15 g of 
Triton X-100 (Pharmacia plusone Chemical) was added in 2 ml of deionized 
distilled water and warmed in 37°C water bath. The Triton X-100 solution 
was added into the melted agarose gel solution and mixed by gentle swirling. 
The temperature of the gel solution was kept at 65�C and 0.715 ml of 
Pharmalyte® pH 2.5 - 5 and 0.235 ml ofAmpholine® pH 3.5 - 9.5 were 
added into the gel solution and mixed by gentle swirling and avoiding bubble 
formation. This gel solution was poured and distributed evenly onto the center 
ofthe pre-warmed gel support. A tip ofthe pipette was used to remove any air 
bubble and to spread the molten gel to the corners of the GelBond. The gel 
was solidified at room temperature for 15 minutes. Complete solidification 
was achieved by placing the gel at 4°C in humidity chamber. 
2.2.5.b Samples Preparation 
Heat inactivation of ALP was employed for flirther differentiation of 
various kinds of ALP isozymes after separation on IEF. Heating of the sample 
at 56°C for exactly 6 min. will preferable destroy the most heat sensitive 
BALP while heating at 65°C for 10 minutes will essentially destroy all form of 
ALP except the placental and placental-like ALP isozyme (Moss, 1982). 
Before running, 100^1 of each sample was incubated at 56°C and 65'C 
water bath for 6 minutes and 10 minutes respectively. After the incubation, all 
samples were centrifuged at 1000 xg for 2 minutes to remove any 
precipitation. The supernatant and the untreated sample were subjected to 
separation by IEF. 
Each samples was diluted with 1% Triton X-100 solution to obtain a 
final ALP activity of 100 U/L before the separation. 
56 
r^ rii6rinlc-厂：fv r^:ii',Gdc-
2.2.5.c Isoelectric Focusing 
IEF was performed by using MuItiphor II Electrophoresis Syst(:m 
(Pharmacia) with Pharmacia LKB MultiDrive XL as power supplier and 
Pharmacia MultiTemp III as cooling system. 
Thermal circulator was turned on and set to 10°C at least 30 mins 
before the experiment and the electrophorsis plate was adjusted to horizontal 
position using a spirit level. Meanwhile, IEF gel was brought back to room 
temperature. Lightly and thoroughly, the gel was blotted with filter paper 
(Whatman) to remove the water film on the surface of the gel. Sample 
application template ( a plastic film with 15 separate 4 x 8 mm square holes 
aligned) was placed on 1.5 cm away from the anode side of the gel. Each 
samples (10^1) was pipetted into the sample wells and allowed to absorb into 
the gel. Moreover, protein markers IEF-MIX 3.6-9.3 (Sigma) (Detail listed in 
Appendix) were added into the first, the middle and the last sample well to 
guide the pH gradient of the IEF gel. Complete absorption of the samples was 
achieved in around 10 minutes. 
Two electrofocusing electrode strips (Pharmacia) was cut into 11 cm 
long strips. The cathode strips was saturated with lM NaOH while the anode 
strip soaked with lM H3PO4. Both strips were blotted thoroughly with paper 
towel and were placed onto the gel surface. The setting of the gel is shown in 
Figure 2.2 
The gel was placed on the electrophorsis plate, with a thin film of 70% 
ethanol between the gel and the plate to ensure efficient cooling. The gel was 
then run in condition with following parameters: 
Prefocusing condition: Voltage 400V 
Current Maximum 
Power 4W 





f ^ i i 
Protein Marker W ' w ^ ^ m 
IEF-Mix3.6-9.3 ^ ^ ¾ ^ 1 一一一 _ :……•: 
\ L ra|_ * I 
1 ^ ^ ^ \_ Cathode Anode J 
1M NaOH 1M 
Figure 2.2. Alignment of the Agarose IEF gel 
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Refocusing Condition Voltage 1500V 
Current Maximum 
Power Maximum 
Time 5 minutes 
In the prefocusing condition, maximum power of 4W and voltage of 
400V with current of around 20 mA were reached initially with gradual 
decrease of the current during the run. In the focusing condition, voltage 
gradually increased with the corresponding decrease in the power and current. 
In general, in the end of the run, the voltage maintained at 800V with Current 
and Power of around 0.8 mA and lW respectively. During the run, it was 
necessary to interrupt the separation and blot the electrode strips with filter 
paper regularly. 
2.2.5.d Protein Detection 
Immediately after the focusing, the electrode strips are removed and the 
gel was cut along the dotted line as shown in figure 2.2 so that the protein 
marker can be stained by Coomassie Blue solution. 
2.2.5.d.i Reagent 
Fixing Solution 
Fixing solution was prepared by disolving 100g of trichloroacetic acid 
(Sigma) and 10 g sulphosalicylic acid (Merck) in distilled water and was 
made up to 1 liter. 
Destaining Solution 
350 ml of95% ethanol and 100 ml acetic acid were mixed and made up 
to 1 liter with distilled water. 
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Coomassie Blue Staining Solution 
1.5 g of Coomassie Blue R 250 (Merck) was dissolved in 500 ml of 
destaining solution by stirring. The solution was then filtered through filter 
paper before used. 
2.2.5.d.ii Procedure 
The gel subjects to the coomassie blue staining was fixed by soaking 
with the fixation solution for 10 minutes. The gel was then washed with 95% 
ethanol and dried to a thin film with hair-dryer. The dried gel was stained in 
the Coomassie Blue staining solution for 5 minutes and then destained in 
several changes of destaining solution until clear background was obtained. 
The destained gel was completely dried in 50°C oven overnight. Proteins were 
stained in dark blue colour. 
2.2.5.e Visualization of ALP Isozyme 
The ALP separated in the IEF gel was directly visualized by its own 
enzyme activity. 2.44 mg of a-naphthyl phosphate (Sigma) and 3.76 mg of 4-
aminodipenylamine diazonium sulfate (Variamine Blue-RT salt, Sigma) were 
dissolved in every ml of AMP buffer to give a final concentration of 4.55 mM 
and 6 mM. This enzyme visualizer was applied onto the gel surface at 37°C in 
dark for 2 - 24 hours to allow colour development depending on the initial 
enzyme activity. ALP catalyzes the hydrolysis of a-naphthyl phosphate and 
forms a-naphthol which in turn couple with the diazonium salt to form a 
reddish-brown insoluble product. After the colour development, the gel was 
destained using destaining solution and dried in 50°C oven overnight. 
For levamisole inhibition staining, AMP buffer containing 0.06 mM 
levamisole was used for preparation of the enzyme visualizer. The gel was 
usually kept overnight at 37°C in dark. 
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2.2.6 Biochemical Differentiation of ALP expressed in Human 
Osteosarcoma 
Themodenaturation and specific inhibition by amino acid are the classic 
separation ofthe ALP isozyme, especially for the confirmation of the presence 
of placental ALP, which is resistant to heat treatment (Whitby and Mc-ss, 
1975) 
2.2.6.a Thermodenaturation of ALP 
ALP samples from the placenta and the two human osteosarcoma cells 
line U-2 OS and SaOS-2 were heated at 56�C and 65�C at 0, 0.5, 1, 2, 5, 10 
and 15 minutes in heat block. After heating, the samples were immediately 
chilled on ice and TALP activity of the samples was measured. The degree of 
inactivation is expressed in percentage of activity remained after heat 
treatment compared with the unheated sample. 
ALP activity after heat treatment 
Percentage ofremained activity = 
ALP activity in the untreated samplf 
2.2.6.b Amino acid inhibition ofALP 
Levamisole and L-phenylalaine were used as inhibitors of the ALP 
isozyme. Levamisole is an specific inhibition of the tissue non-specific ALP 
while L-phenylalaine at a concentration of 5 -10 mM, inhibited 80% of the 
placental and intestinal ALP activity with little effects on the bone and liver 
ALP activity. (Harris, 1989; Moss, 1986) 
AMP buffer containing different concentration of inhibitors was used to 
prepare the pNPP substrate solution for ALP activity measurement. For 
levamisole, substrate solution containing final concentrations ofO, 0.5, 1, 2.5 
and 5 mM of Levamisole were used for the measurement. 
For L-phenylalaine, substrate solution containing final concentratior of 
0, 1, 5, 10 and 20 mM of L-phenylalaine were used for the ALP activity 
61 
“�nlnrinlf：- f: rv^6iiiodc-
measurement. Again, the degree of inhibition is expressed in percentage of 
activity remained after addition ofinhibitors. 
ALP activity after inhibition 
Percentage of remained activity = ^ 7 ^ ~ 广 . . . ： 
ALP activity in the untreated sample 
2.2.7 Immunohistostaining ofplacental ALP in human Osteosarcoma 
2.2,7.a Reagent 
Poly-L-Lysine solution 
0.1% (w/v) poly-L-lysine (Sigma) solution was prepared by dissolving 
O.lg of poly-L-lysine in dd H2O. The poly-L-lysine solution was filtered 
throught a 0.22 p,m sterile membrane (Millipore) and stored in 4°C. 
Neutral Buffered Formalin Solution 
100 ml of Formalin (40% w/v formaldehyde) was mixed up with PBS to a 
final volume of lL. 
ABC Regent 
The ABC reagents were prepared by mixing 2 jLil of reagent A (Avidin DK) 
and 2 p,l of reagent B (Biotinylated Horseradish Peroxide H) into 1ml ofPBS. 
The ABC reagent was allowed to stand 30 mins in 4°C before use. 
0.1m Tris Buffer (pH 7.2) 
6.05g of Tris-Base and 9 g ofNaCl was dissolved in 900ml of ddH2O. 
pH of the solution was adjusted with lM HC1 and the solution was made up to 
1 L. 
Diaminobenzidine tetrahydrochloride (DAB) colour dievelopment 
DAB concentrate was prepared by dissolving lmg of DAB into 1 ml 
ddH2O. Just before use, 0.02ml ofDAB concentrate and 3.4^il of30% H2O2 
(Merck) were added into 1 ml ofO.lM Tris Buffer (pH 7.2). 
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2.2.7.b Preparation ofhiiman osteosarcoma cell line 
Round glass slide with diameter of 1 cm were clean by soaking in 
acetone for 15 mins followed by 0.2M HC1 for another 15 mins. The glass 
slid were raised with ddH2O and baked at 180°C overnight. The hot glass slid 
were cooled down and than coated with the poly-L-lysine solution for 15 
mins. The coated slid were raised with steriled ddH20 for 15 min and then air 
dried under UV light. 
Both U-2 OS and Sa OS-2 cell were cultured according to previous 
sections. After confluent, the cells were released by trypsinization. The 
released cells were resuspened in plain medium to a concentration of lxlO^ 
cells/ml. 200^il of the cell suspension were seeded onto the glass slid pla^;ed 
in a 25mm culture dish for 30 mins. 2 ml of plain medium were added into the 
culture dish and placed in the incubator overnight. The medium was then 
removed and the seed cells were washed with PBS followed by a 15 mins 
fixation using neutral buffered formalin. The seeded cells were then washed 
in ddH2O for 5 mins and follow the immunostain procedures. 
2.2.7.c Preparation ofhiiman osteosarcoma tissue 
Seven human osteosarcoma tissues embedded in paraffin were obtained 
from the Department of Anatomical and Cellular Pathology, CUHK. 7 ^m 
paraffin sections were obtained by microtome. Routine Hematoxylin and 
Eosine stain were applied to all sections to ensure the presence of osteosaroma 
tissue within the sections. 
The paraffin sections were de-waxed in 2 wash of xylene, each for 5 
mins, and then hydrated with decreasing concentration of ethanol and finally 
rinised in running water. The sections were then ready for immunostaining. 
Cytosection of human placenta tissue and human liver tissue section 
were used as the positive and negative control for the immunohistostaining. 
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2.2.7.d Immunohistostaining 
All sections were quenched for endogenous peroxidase by incubating in 
0.02% H202 for 10 mins in room temperature. The section were then block 
with 1% Bovine Serum Albumin (BSA) in PBS (BSA/PBS) for 20 min. After 
blocking, the 1% BSA/PBS were wraped dry. Primary antibody 1:20 (Rabbit 
monoclonal antibody against human placental ALP, Immiinodiagnostika & 
Biotechnologie, produktioii & Vertriebs GmbH, Germany) diluted in 0.1% 
BSA/PBS were applied on the sections incubated at 4°C overnight. 
After the incubation, the primary antibody was wrap off and the 
sections were washed 3 times by soaking in 0.1% BSA/PBS solution. The 
sections were then incubated with Biotinylated 2nd antibody (against rabbit 
IgG) provided by Vectastain® ABC kit for 30 mins. After incubation with the 
2nd antibody, the sections were washed 3 times in 0.1% BSA/PBS (each '5 
mins) and then incubated with the ABC reagent for another 1 hour. 
The ABC reagents were removed by washing with 3 fold of 0.1% 
BSA/PBS and the DAB colour development were applied on the section and 
incubated for 10 mins in dark. After the development of reddish brown 
colour, the sections were washed with running water and counterstain with 
Hemotoxylin. Sections were then dehydrated with increasing concentration of 
ethanol and finally in xylene and then mounter with a coverslid in histomount. 
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3. Plasma BALP measurement in Osteosarcoma patients 
3.1 General Information ofthe Patients 
Between 1990 to May 1997, 49 patients who have been diagnosed with 
primary osteosarcoma were recruited for the study. All the patients were 
referred to the Department of Orthopaedics & Traumatology, Prince of Wales 
Hospital for their management. 
Diagnosis of osteosarcoma was based on clinical, radiographic findings 
and biopsy. Biochemical investigations included blood tests: CBP, ESR, 
LDH, plasma calcium, phosphate and alkaline phosphatase. Radiological 
investigations included the CXR, X-ray of affected extremity or pelvis, bone 
scans and MRI. These investigations helped to stage the disease and detect 
any metastasis. The diagnosis was confirmed by histology of the biopsy 
tissue. 
3.1.1 Age and Sex Distribution 
The details of all osteosarcoma patients are listed in Table 3.1. The age 
distribution of the 49 patients with proven osteosarcoma is shown in Figure 
3.1. Patients' age ranged from 9 to 61, with a mean of20.8. Highest incidence 
of osteosarcoma occurred at age 18 (12.24%). A peak was observed in 
adolescence, 65.3% of the patients under 20 years of age. There was a male 
predominance, with 65.3% male patients and 34.7% female patients. 
3.1.2 Sites 
In 85.7% of patients, the primary site of osteosarcoma was in the long 
bones. There were 21 cases in the femur, 17 cases in the tibia and 4 cases in 
the humerus. In the remaining 7 cases, the affected bone was the peMs. 
Metastases at admission were detected in 5 patients with sites of metastasis at 
lung and ribs. One of the patients with primary lesion in the humerus had 
multiple metastasis in the skull, cervical spine, ribs, pelvis and the femur. 
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3.1.3 Treatment and survival rate 
All except 2 patients with low grade sarcoma and 1 patient who refosed 
treatment, patients received neoadjuvant chemotherapy according to a 
modified Rosens T10 protocol developed in 1974 (Rosen et aL, 1974). 
Preoperative regime included the use of cisplatinum, adriamycin and high dose 
methotrexate as shown in Table 3.2. Most patients received 2 to 4 courses cf 
pre-operative chemotherapy. 
Wide excision of the lesion and allograft reconstruction was performed 
after week 10 of pre-operative chemotherapy. Rotationplasty was performed 
in one patient. For patients with local recurrence, amputation was performed to 
ensure the complete removal of the tumor. Post-operative chemotherapy was 
begun 2 weeks after the surgery with a similar protocol as the pre-operative 
chemotherapy. Patients with favorable response toward the chemotherapy 
(Huvo's III and IV based on the histological examination on the excised tumor 
specimen received) repeated treatment with week 1-4 cycles for three times. 
Patients with unfavorable response (Huvo's I & n) were switched to another 
salvage protocol listed in Table 3.3. 
Follow-up investigations after the completion of the chemotherapy 
included: Blood test in every 3 months in the first 4 years and then half-yearly 
from the 5th year onward; CT Thorax for every 4 to 6 months in 1-4 years and 
than annually from 5th year; Bone Scan biannually in the first 2 years, 
annually in the 3rd and 4th year. 
The longest follow-up time for our patients is 7 years with mean 
follow-up time of2.5 years. The 2 years survival rate is 64.5%. Main cause 
of death was local recurrence and metastasis. One patient died from 
adriamycin toxicity during chemotherapy. The average time of recurrence is 
10 months and average time for metastasis (exclude metastasis detected at 
admission) is 28.68 months. 
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Patient Sex Site Date of Metastasis Recurrence Die ofdisease FoIlow-up 
Code /Age Diagnosis Period 
" B W F/12 “ Femur 14/2/96 7[dmission 一 — 15 months 
K S W 1 / 1 4 F e m u r ~ 20/3/96 一 A d m i s s i o ~ 5 months 
^ L F/18 Pelvis l 2 / 9 4 " I ^ o n t h s ^ m o n t h 
C C K "?/18 Tibia — — 1 4 m o n t h � 24 months 
T C Y F/18 Tibia 11/9/91 1 3 m o n t h r " 一 6 Yea-
K P ~YI22 Tibia 一 1 2 m o n t h s ~ 19 months 
HSF F/26 Femur 9/8/96 1 month 8 months~~ 
K C Y M/10 Tibia 29/8/91 — 9 months ~ ~ " 6 Years 
T H L "M/10 Tibia 8/96 Admission 5 months 11 months 一 
S K W 1 ^ 1 1 F e m u r 一 13/9/91 — 30 m o n t h s ~ 35 montj^ 
W C K M/12 Tibia 11/3/92 9 m o n t h s ~ 一 5 Years 
" V & Y M / 1 3 ~ Tibia 29/9/96 ‘ 8 months “ 10 months 
C L Y M A 4 Pelvis 一 20/1/92 ~ lOmonths— 一 5 Years 
C S L M/15 l ^ m e r u s "Ti?7/95 "Admission “ 10 months 
P T M M/16 Femur 14 months 9 months 24 months 
" ^ H W " ^ 1 7 Femur 14/795 10 months "TFmonths — 一 22 months 
^ L M / 1 7 ~ Tibia 24/12/96 "Admission “ 5 months ~ 
C H L M/18 T e m u r 12 months 16months 
Y K C M/18 Pelvis 6 months 6 months 11 months 
A K M ~M/18 Pelvis 15/7/92 13mont"KT" U ^ o n t h s 
M C M M/21 T e l v i s 一 ~6 months 2 months — 9 months 
S C M!2A Tibia 6 months 4 months 9 months 
L M C 'M/30 T d v i s 21/9/92 ^ m o n t h s 26 months 
T Y C M/38 Femur 24/4/92 6 months “ 5 Years 
L F H 'M/40 Temur 2/11/92 ^ m o n t h s 36 months 
W C W M/45 ~Femur 8/96 ~5 months 9 m o n i h s ~ 
T P K T T T T " Tibia 9/6/96 ~ T r ^ ) ^ ^ 
Y L P F/12 Humerus 一 5 Year 
T Y M ~¥n2~~ Tibia 11/7/95 “ “ 2 Years 一 
l v l L K ~F/l2 Femur 14/1/97 — 4 m o n t h s ~ 
" ^ S P T 7 l 8 H u m e r i ^ 23/9/91 — 6 Years 
~CY ~mO Tibia 12/89 一 “ " ~ 7 Years 
" ^ M S ~FJTr~ Femur 2/4/97 _ 1 month 
T W F/36 Tibia ~ 2/9/91 _ 6 Years 
" C K L F/9 Femur 一 27/12/96 “ _ 6 month 
L S F ~ m ~ Femur 18/3/97 “ — 2 months 
_ Y S M ^ / 1 1 Femur 1990 — — 6 Years 
" W T F M / l T " Femur — 29/12/94 一 28 rnomhs" 
T C W J " W T " Pelvis 16/12/92 “ — 24 month 
l i W H " W i 2 Femur 29/1/97 _ — 4 m o n i T ^ ~ 
T W S " W l 3 Tibia 一 1993 一 3 Years 
~LKH M/14 Humerus — 一 4 Years 
T C K ~ W n ~ Femur — 7/5/96 — 2 Y e a i ^ 
""TCC M/20" Tibia 一 1/10/92 ~ — 5 Years 
^ M W 1 ^ 2 1 Femur 一 一 — 4 Years 
l v I S K ~ w U ^ Tibia 一 — ~5 Years 
" ^ C W ~ ^ m S ~ Tibia — 10/94 ~1.5 Y e i r T " 
L C S 1^ / 5 1 Femur 20/12/96 — — 5 m o r . t l ^ ~ 
^ H W M/58 Femur 11/7/96 9m^nths 










































































































1 Day 1 Cisplatinum lOOmgW 
Day 1 - 2 Adriamycin 30 mg/m 
_3 Methotrexate 8 g!m 
_4 Methotrexate l2g!m 
5 - 8 Repeat weeks 1 - 4 
Table 3.2. Pre-operative chemotherapy (Rosen T10) protocol used 
in Prince ofWales Hospital. 
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Week Treatment 
16 Day 1 - 3 VP16 lOOmgW 
Ifosfamide 2.5 g!m 
19 Day 1 Cisplatinum 100 mg!m 
Day 1 - 2 Adriamycin 30mg/m^ 
22 -27 Repeat weeks 16 - 19 for 3 cycle 
40 Day 1 - 3 VP16 lOOmgW 
Ifosfamide 2.5 g!m 




3.2 Clinical Significance of Plasma Bone Specific Alkaline Phosphat ise 
(BALP) Activity measurement in Osteosarcoma Patients 
3.2.1 Plasma BALP Activity measurement 
Two different methods of BALP measurement were used in this study. 
WGL precipitation assay using A-Gent Alkaline Phosphatase Test reagent and 
ABBOTT VP system (refer to methodology section 2.14a) were previously 
adopted in the Orthopeadic and Tramatology Department, Prince of Wales 
Hospital before the development ofALKPHASE-B ELISA Kit for the BALP 
isozyme measurement. 
In addition, part of the BALP measurement was done in the main 
laboratory in the Chemical Pathology Department, Prince of Wales Hospital. 
WGL precipitation assay using ROCHE ALP IFCC reagent and COBAS 
MIRA system (refer to methodology section 2.14c) was adopted in the 
Chemical Pathology Department. 
All the Bone-ALP measurement units were in ^JfL, which is defined as 
pmol of p-nitrophenyl phosphate hydrolyzed per minute. However, since the 
methodology and reagents were different, the correlation between different 
methods was established to allow comparison of the data. All the Bone-ALP 
measurements are finally presented using the unit defined in ALKPHASE-B 
ELISA kit. The correlation ofBone-ALP measurement between ALKPHASE-
B and ABBOTT VP system is shown in Figure 3.2. The correlation of Bone-
ALP measurement between ALKPHASE-B and COBAS MIRA system is 
shown in Figure 3.3. 
For the BALP level measured by Wheat germ lectin binding as.^ ay 
measured by the ABBOTT method, the values should be converted by the 
following equation, which is the best-fitted linear equation obtained on Figure 
3.2: 
ALKPHASE-B = 0.5498 x ABBOTT + 0.8774 
The correlation (R^) of values measured by these two methods are 0.9687, 
showing a valid conversion. 
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For the BALP level measured by the Chemical Pathology Department, 
the value should converted to compatible unit by the equation, which is the 
best-fitted linear equation obtained on Figure 3.3: 
ALKPHASE-B = 0.772 x COBAS MIRA - 0.5216 
The correlation (R2) of values measured by these two methods are 0.9075. 
3.2.2 Normal Reference ofPlasma BALP determination 
Normal subjects from the local Chinese population in different age 
groups were recruited for the determination of normal reference value of 
plasma Bone-ALP level. Normal subjects had no past history or present sign or 
symptoms of liver and metabolic bone disease at the time of recruitment. The 
Department of Pediatrics, Prince of Wales Hospital, kindly provided the 
plasma samples of subject with age under 12. 
Subjects were divided into 3 groups according to their ages: N1 (ige 
below 12); N2 (age between 12 and 16) and N3 (age above 16). According to 
the International Federation of Clinical Chemistry (IFCC) and the International 
Committee for Standardization in Hematology (ICSH) recommendation 
(Solberg, 1987), the normal reference of plasma bone-ALP level is calculated 
and summarized in Table 3.4. 
Due to the limitation of blood sample collection in Group N1 and N2, 
normal range of plasma BALP level in this two age groups are estimated by 
the range of the plasma BALP activity. The normal range of plasma BALP 
level in N1 is 73.6 to 217.7 U/L with mean value of 128.28 U/L. For group 
N2, the normal range is 21.7 to 136.8 U/L with mean of75.31 U/L. 
For plasma BALP normal reference determination in group N3, non-
parametric methods were used to determine the lower (0.025 fractile) and 
upper range (0.975 fractile) of the reference, which contains the central 0.95 
fraction of the reference distribution. The calculated range is 8.9 to 59.5 U/L 


























































































































































































































































































































































































































































When we compare the plasma BALP level in three groups, using one-
way ANOVA Duncan test (Figure 3.4), there is a significant difference 
between the three groups (p <0.05), with highest plasma BALP level in N1 and 
N2 and lowest in N3. 
3.2.3 Diagnostic value of Plasma BALP measurement in Osteosarcoma 
3.2.3.a Plasma BALP level at admission 
Blood samples of the osteosarcoma patients were collected during 
admission, usually the day before the biopsy. Plasma BALP activity was 
measured by either one method described in the methodology section. Since 
no treatment was done before the confirmation of diagnosis by biopsy, tlie 
plasma BALP level at admission (BALP-Adm) was used to represent the 
initial plasma BALP level before any treatment. Patients were divided into 
three groups according to their ages at diagnosis, namely T1 with age below 
12; T2 with age between 12 to 16 and T3 with age above 16. The BALP-Adm 
at these three age groups is shown in Table 3.5-7 respectively. 
By using 2-Way ANOVA analysis, BALP-Adm of the patients was 
compared with the plasma BALP of the normal with respect to both the age 
group and tumor-bearing factor. Results show that there is significant 
difference (p < 0.001) in the plasma BALP level between tumor bearing and 
non-tumor bearing, independent of age (Figure 3.5.). However, there is no 
significant difference (p = 0.727) in the plasma BALP level between 
individual age groups, independent ofthe tumor-bearing factor. 
Moreover, the interaction between age group and tumor bearing factors 
on the plasma BALP is significant (p = 0.003). This implies that between 
different age groups, the difference in plasma BALP is not the same. As a 
result, Student's t-test was used to compare the plasma BALP level between 
the normal subjects and osteosarcoma patients in each individual age group. 
Independent-samples Student's t-test was performed between the 
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< 丨 ^ ^ ^ ^ ^ B 
1 I — • JH I 
^ ^ 二 二 - ; 
0 � 
-100 
N1 N2 N3 
Age Group 
Figure 3.4. Boxplot of pIasma BALP level of Normal Subjects in 
different age group 
* N1 = age below 12 (n=23); N2 = age between 12 to 16 (n= 10) and; 
N3 = age above 16 (n=103). 
Analysis done by One-way ANOVA ,with p < 0.05 
For Boxplot, the upper bar and lower bar represent 95 and 5 percentile of the data 
respectively; the upper and the lower margin of the box respresent 75 and 25 
percentile of the data and the middle line respresents the mean of the data. 
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different age group. The results are shown in the form of box plot in Figure 
3.6-8. 
In age group 1 (age < 12)，there is no significant difference between the 
plasma BALP from the normal subjects and the BALP-Adm of the 
osteosarcoma patients (p = 0.145). In group 2 (age 12 -16) and group 3 (age > 
16), BALP-Adm is significantly higher than the plasma BALP in normal 
group, with two tailed significance of p = 0.006 and p < 0.001 respectively. 
3.2.3.b Plasma Total ALP level at admission 
Plasma total ALP level at admission (TALP-Adm) was also measured 
in the admission plasma sample and was recorded in Table 3.8. Student's t-
test was used to compare TALP-Adm with total plasma ALP of the normal 
subjects. We found that the plasma TALP-Adm in osteosarcoma patients is 
significantly higher (p < 0.001) than the plasma ALP of normal subjects. 
(Figure 3.9.) 
Plasma TALP-Adm in different age groups (T1, T2 & T3) were also 
compared with the age matched normal reference Nl，N2 & N3 respectively 
using Student's t-test. The results were shown in Figure 3.10 - 3.12. In both 
group T1 and T2, there is no significant difference between the plasma TALP-
Adm and the plasma total ALP level, with p = 0.273 and p = 0.096 
respectively. In group T3, plasma TALP-Adm level is significantly higher 
than the plasma total ALP of the normal group (N3), with p = 0.002. 
3.2.4 Prognosis Value of Plasma BALP measurement in Osteosarcoma 
Patients 
3.2.4.a Correlation of plasma BALP-Adm with the local relapse of the 
disease 
Patients with the completion of the post-operative chemotherapy .ind 
their plasma BALP-Adm were shown in Table 3.9. Seven out of 41 patients 
experienced local recurrence after the operative removal of the tumor with an 
average relapse time of 9.7 months. By using Student's t-test, we found that 
the BALP-Adm of the patients who experienced local recurrence is 
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Patient Code Sex/Age BALP-Adm (U/L)* 
CKL F ^ 1 9 ^ 
LSF F ^ 44.88 
KCY M/10 220.80 
T| M/10 244.84 
WL F/11 — 9 9 . ^ 
SKW M/11 — 2 7 1 . 5 
7sM |M/11 566.l3 
Table 3.5 Plasma BALP level at admission of patients in age group 
T l (below 12) 
* BALP unit are expressed in ALKPHASE-B unit. 
Patient Code Sex/Age BALP-Adm (U/L)* 
YLP ^ 521.35 
BWY F m 102.80 
LYM F ^ 107.66 
MLK F/12 97.22 
WCK ]Vm 290.60 
TCWJ M ^ 215.69 
HWH W ^ 184.12 
LWS J ^ 631.75 
YCY M m 64.64 
KSW F m 1057.49 
LKH M m 326.03 
CLY M/14 178.80 
CSL l _ 5 203.26 
Table 3.6. Plasma Bone ALP level at admission of patients in age 
group T2 (between 12 to 16) 
* Bone ALP unit are expressed in ALKPHASE-B unit. 
79 
1 
Patient Code Sex/Age BALP-Adm (U/L)* 
PTM M/16 789.23 
CHW M/17 — 1 6 8 ^ 
LCK M/17 — 3 4 ^ 
SHL M/17 — 7 1 ^ 
TCY F/18 — 1 1 9 ^ 
KSP F m 87.99 
CML ? m 702.77 
CCK F m 691.96 
CHL M/18 319.09 
AKM M/18 494.92 
YKC M/18 837.10 
TCC j ^ 81.75 
AMW U|2A 289.75 
MCW M ^ 790.01 
KP F/22 527.53 
MSK M/23 547.60 
^ M/24 934.37 
HSF R ^ 215.38 
CY F ^ 624.03 
LMC M/30 115.80 
LW F ^ 67.56 
TYC M/38 158.37 
LFH M/4Q 245.75 
WCW M/45 228.65 
LCS M/51 1745.93 
HHW 一 M/58 28.97 
^ S |F/61 4 4 4 ; 
Table 3.7 Plasma Bone ALP level at admission of patients in ap,e 
group T3 (above 16) 
* BALP unit are expressed in ALKPHASE-B unit. 
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Figure 3.5 Boxplot of plasma BALP level in Normal Subjects and in 
osteosarcoma patients, independent of age. 
Analysis done by 2-Way ANOVA, p < 0.005 between the different of 
the noraml subjects (n =136) and osteosarcoma patients (n = 47). 
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Figure 3.6. Boxplot of Plasma BALP level in Normal Subjects (N1) 
and Osteosarcoma Patients (T1) with age below 12. 
For osteosarcoma patients, the plasma BALP level is the BALP-Adm. 
Analysis done by Student's t-test, with p > 0.1，between the difference 
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Figure 3.7. Boxplot of Plasma BALP level in Normal Subjects (N2) 
and Osteosarcoma Patients (T2) with age between 12 and 
16. 
For osteosarcoma patients, the plasma BALP level is the BALP-Adm 
Analysis done by Student's t-test, with p < 0.01, between the different 
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Figure 3.8. Boxplot of Plasma B A L P level in Normal Subjects (N3) 
and Osteosarcoma Patients (T3) with age above 16. 
For osteosarcoma patients, the plasma BALP level is the BALP-Adm 
Analysis done by Student's t-test, with p < 0.001，between the 
difference of normals subjects N3 (n = 103) and osteosarcoma patients 
T3 ( n = 26). 
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Patient Code Sex/Age Group Plasma TALP-adm (U/L) 
CKL “ F/9 ~ T T ~ 1 7 2 . ^ 
"KCY — M/10 一 T1 5 2 T O 
LDK F/11 ~ T 1 136.8 
� l M/11 ~ T 1 402.85 
SKW ~ M/11 • T1 592.42 
BWY 一 F/12 _ T2 122.71 
LYM F/12 ^ T ^ 163.35 
MLK F/12 " " T ^ 128.85 
HWH — M/12 “ T2 201.97 
WCK — M/12 “ T2 650.98 
LWS M/13"" T2 608.28 
YCY M/13— T2 183.84 
KSW — F/14 _ T2 1595.88 
LKH — M/14 _ T2 370.34 
CLY — M/14 _ T2 394.75 
CSL — M/15 - T2 348.14 
PTM _ M/16 - T3 397.19 
CHW M/17— T3 — 149.35 
LCK M/17— T3 45.92 
SHL M/17— T3 77.7 
CHL M/18 ~ T3 321.54 
KSP F/18 — T3 226.36 
AKM M/18 T3 1093.91 
TCY F/18 — T3 267.85 
TCC ~~M/20 T3 208.06 
MSK M/23 ~ T3 347.16 
SC ~M/24 T3 292.25 
HSF F/26 T3 159.1l" 
CY F/3Q T3 — 187.32 
LMC M/30 T3 271.5l" 
LW M/13 T3 193.42 
TYC M/38 T3 376.45 
LFH M / 4 0 ~ T3 186.10 
WCW M/45 T3 335.28 
HHW M/58 — T3 56.69 
Table 3.8 Plasma Total ALP level at admission of patients 
Patients is divided into 3 group according to their age at diagnosis. 
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Figure 3.9 Boxplot of plasma Total ALP level in Normal Subjects 
and in Osteosarcoma Patients, independent of ages. 
Analysis done by 2-Way ANOVA, p < 0.001，between difference of 
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Figure 3.10. Boxplot of Plasma Total ALP level in Normal Subjects 
(N1) and Osteosarcoma Patients (T1) with ages below 
12. 
For osteosarcoma patients, the Plasma Total ALP level is the TALP-
Adm 
Analysis done by Student's t-test, with p > 0.1，between normal 
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Figure 3.11. Boxplot of Plasma Total ALP level in Normal Subjects 
(N2) and Osteosarcoma Patients (T2) with ages 
betweeen 12-16. 
For osteosarcoma patients, the Plasma Total ALP level is the TALP-
Adm 
Analysis done by Student's t-test, with p > 0.05, between different of 
normal subjects N2 (n = 10) and osteosarcoma patients T2 ( n = 11). 
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Figure 3.12. Boxplot of Plasma Total ALP level in Normal Subjects 
(N3) and Osteosarcoma Patients (T3) with ages above 
16. 
For osteosarcoma patients, the Plasma Total ALP level is the TALP-
Adm 
Analysis done by Student's t-test, with p < 0.005, between difference 




significantly higher (p < 0.001) compared with the patients who did not have 
local recurrence (Figure 3.13). 
3.2.4.b Correlation of plasma BALP-Adm with survival rate ofthe 
patients 
3.2.4.b.i One year Survival Rate 
Plasma BALP-Adm of patients with at least 1-year follow-up period 
was listed in Table 3.10. Five out of33 patients died from the disease within 
one year of studies. Among these 5 patients, 4 of them received operative 
removal ofthe osteosarcoma and one of them died before the surgery. Figure 
3.14 shows that the plasma BALP-Adm level is significantly higher compared 
with those patients who died from the disease within one year than patients 
who survived (p = 0.001). 
3.2.4.b.ii Two-year Survival Rate 
Patients with 2 years follow-up periods and their BALP-Adm are 
shown in Table 3.11. 35.5% of the patients died of the disease mainly due to 
local recurrence and metastasis of the tumor. When compared with BALP-
Adm of patients who survived, patients who died within 2 years have a 
significantly higher BALP-Adm (p = 0.001). Figure 3.15 demonstrates tlie 
difference in plasma BALP-Adm in these two groups. 
3.2.4.b.iii Three year survival rate 
Patients with 3-year follow-up periods and their BALP-Adm are shown 
in Table 3.12. Only 53.3 % of patients survived three years or more. Again, 
plasma BALP-Adm of patients who died within 3 year studies is significant 
higher (p = 0.05) than the patients who survived. Results are shown in Figure 
3.16. 
3.2.4.c Correlation of the plasma BALP-Adm with the tumor volume 
The Diagnostic Radiology & Organ Imaging Department, Prince of 
Wales Hospital calculated tumor volume of the patients. This value is 
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estimated from the Magnetic Resonance Imaging (MRI) of the patients using 
Ellipsoid Approximation. Patients' tumor volume and their plasma BALP-
Adm are shown in Table 3.13. We fmd that there is a significant linear 
correlation (p = 0.045) between the BALP-Adm and the tumor volume (Figure 
3.17). The correlation found is 0.6127 with R^ = 0.3753. 
3.2.5 Using Plasma BALP measurement for monitoring of the disease. 
3.2.5.a Effectiveness of Pre-operative Chemotherapy 
The effectiveness of the pre-operative chemotherapy is reflected by the 
tumor necrosis of the resected tumor specimen. After the operative removal of 
the tumor, the specimen is subject to histological studies to determine how 
much of the tumor is killed by the pre-operative chemotherapy. The 
Anatomical and Cellular Pathology Department, Prince of Wales Hospital 
determined the degree of tumor necrosis, i.e. percentage of tumor cells killed. 
The tumor necrosis of the patients receiving pre-operative chemotherapy and 
excision of the tumor is presented in Table 3.14. 
Patients' plasma BALP level after the pre-operative chemotherapy was 
compared with the age-matched normal reference values. Patients whose 
plasma BALP levels returned to the age-matched normal range after the 
chemotherapy are classified as "DROP". Patients with their plasma BALP 
level higher than the age-matched normal range even after the chemotherapy 
are classified as "REMAIN". 
Independent sample Student's t-test analysis shows that, the degree of 
tumor necrosis in the "DROP" group is significantly higher than whose 




3.2.5,b Change ofPIasma BALP level during the treatment 
3.2.5.b.i Monitoring of pre-operative chemotherapy 
In order to monitor the change of plasma BALP activity in the 
osteosarcoma patients during treatment, blood samples were collected at 
different time intervals, (i) at admission; (ii) during the preoperative 
chemotherapy; (iii) day before and after the resection of the tumor; (v) during 
postoperative chemotherapy and (vi) at every follow-up clinic. Blood samples 
were also collected during (vii) relapse or (viii) secondary metastasis. 
Patients were divided into 2 groups according to their response to 
chemotherapy. Classification is based on (1) clinical observation if patients 
have not had their tumor resected or (2) by the degree of patients' tumor 
necrosis following tumor resection. Patients with degree of tumor necrosis 
higher than 80% were considered as good responders to chemotherapy while 
those were lower than 50% were considered as poor responder. 
Figure 3.19 shows the change of plasma BALP activity during the pre-
operative chemotherapy of patients that's responded well toward the 
chemotherapy. There is a general trend that the plasma BALP levels dropped 
during the chemotherapy in whose patients with initial high values. Most of 
the patients have their plasma BALP drop back to normal range before the 
operation. 
The change of plasma BALP levels in whose patients with poor 
response toward the chemotherapy was shown in Figure 3.20. Compared with 
the patients with good response, the plasma BALP levels of patients with poor 
response did not show significant drop during the chemotherapy. Large 
fluctuation of the plasma BALP was observed in three of the patients. One 
patient (KSW) died before the operation and the other 2 patients (TI and SC) 
also died within half year of operation. Moreover, the plasma BALP levels did 
not return to normal even after the removal of the tumor. 
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Patient Code Sex/Age Plasma BALP-Adm (U/L) Date ofRecurrence 
TI "M/10 - 244.84 5 MONTH 
PTM _M/16 “ 789.23 9 MONTH 
CHW ~M/17 “ 168.72 18 MONTH 
CML "F/18 702.77 24 MONTH 
YKC _M/18 — 837.10 6 MONTH 
MCW —M/21 — 790.01 2 MONTH 
SC _M/24 - 934.37 4 MONTH 
CKL F/9 — 192.58 
KCY ~M/10 2 2 ^ ‘ ~ 
Wl M l 9 9 ^ ‘~~ 
YSM M/11 566.13 
SKW "M/11 271.88 
YLP "F/12 — 521.35 
BWY ~fn2 I o I ^ 
LYM "F/12 107.66 
MLK f J n 9^22 
WCK "M/12 290.60 
TCW _M/12 — 215.69 
LWS M/13 — 631.75 
YCT M/13 — 64.64 
L K H M / 1 4 326.03 
C L Y M / 1 4 178.80 
L C K M / 1 7 34.54 
S m M/17 71.^ 
C ^ fTTs 691.% 
TCT f n S 119.78 
K ^ F/18 87.99. 
C H L M / 1 8 319 .09" 
A m M/18 4 9 4 ^ 
T ^ M/20 81.75 
A M W M/21 — 289.75 
P K w o k F/22 — 527.53 
MSK M/23 ~ 547.60 
H S F m e 2 1 5 . 3 8 
CT P7l0 6 2 4 ^ 
n ^ M/30 — 115.80 
LW F/36 — 67.56 
T Y C M/38 — 158.37 
LFH M/40 ~ 245.75 
WCW M/45 228.65 
HHW M/58 — 28.97| 
Table 3.9. Plasma BALP level at admission of patients with / 
without local recurrence. 
All patient with complete post-operative chemotherapy done. 
Date of the recurrence were counted from date of diagnosis 
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Figure 3.13. Boxplot of Plasma BALP-Adm level in Osteosarcoma 
Patients with or without Local Recurrence. 
Analysis is done by Student's t-test, p < 0.001，between the 
difference of non-recurrent patients (n = 34) and the recurrence 
patients ( n = 7). 
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Patient Code Sex>^ Age Die of disease within 1 year Plasma BALP-Adm (U/L) 
T^ M/10 11 month 244.84 
YKC 一 M/18 11 month S37?W 
KSW 一 F/14 “ 5 month 1057.49 
MCW “ M/21 — 9 month 7 9 ^ 
^ M/24 9 month 934.37 
KCY M/10 220.80 
YSM WTl 5 6 ^ 
SKW ~ W n ~ — 271.88 
YLP F/12 “ - 521.35 
WCK “ M/12 " m M 
TCWl M7l2 n s ^ 
BWY FlU I o I M 
LYM ¥JU l07M 
EW^ Wl3 6^775 
L ^ M7T4 3l6.M 
CT7 M/14 V 7 ^ 
PTM M7l6 7 8 ^ 
CHW W n TKi2 
1 ^ M/17 34.54 
CHl M/18 3 l 9 m 
CML PTTS 702.77 
C ^ F/18 691.96 
A m M/18 494.92 
TCY FVl8~~ 一 119.78 
^ F/18 87.99 
T ^ M/20 — 81.75 
A ^ M/21 289.75 
l P F/22 — 527.53 
MSK M/23 — 547.60 
CT MO 624.03 
m C M/30 “ 115.^ 
r W F/36 — 67l6 
TYC M/38 158.37 
T m M/40 245.75 
Table 3.10. Plasma BALP-Adm of patients with at least one year 
follow-up period and their survival. 
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One year survival rate of patients 
Figure 3.14 Boxplot of Plasma BALP at admission in osteosarcoma 
patients with one-year survival or died of disease within 
one year. 
Analysis is done by Student's t-test, p = 0.001, between the 
difference of survivied patients (n = 28) and patients who died of 
disease (n = 5). 
96 
T^ient Code Sex/Age |Die of disease within 2 years Plasma BALP-Adm (U/L) 
KSW 一 F/14 - 5 months 1057.49 
MCW — M/21 9 months 790.01 
^ M/24 9 months 9 ^ 7 
TI — M/lQ 11 months 244.^ 
YKC — M^8 11 months ^：10 
AKM M/18 13 months 494.92 
CHL M/18 16 months 319.09 
KP ¥ r n 19 months 527.53 
TCWJ M/12 24 months 215.69 
PTM M/16 24 months 789.23 
CCK FTTS 24 months 691.96 
KCY M/10 5 5 ^ 
YSM M m 5 6 ^ 
SKW WTl ~"" 2 7 L ^ 
YLP~ ¥ / r r ~ 521.35 
W ^ M/12 290.60 
LWS M7n 6HJ5 
L ^ M/14 — 326.03 
CLY M/14 178.80 
LCK M/17 — 34 5l 
C ^ F/18 702^77 
TCY F/18 — 119.78 
K ^ FVlS 87.99 
T ^ M/20 81.75 
AMW M/21 一 289.75 
M ^ M/23 547.60 
CT FVlO 624.03 
LMC M/30 — 115.80 
UW F/36 — 67.56 
TYC M/38 158.37 
L m M/4Q 245.75 
Table 3.11. Plasma BALP-Adm of patients with at least two year 
follow-up period and their survival. 
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Figure 3.15 Boxplot of PIasma BALP at admission in osteosarcoma 
patients with two-year survival or died of disease within 
two-years. 
Analysis is done by Student's t-test, p = 0.001，between the 
difference of survived patients (n = 20) and patients who died of 
disease (n = 11). 
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Patient Code Age/Sex Die of disease within 3 years Plasma BALP-Adm (U/E^ 
KSW F/14 5 months 1057.49 
MCW — M/21 9 months 790.01 
SC — M/24 9 months 934.37 
TI M/10 11 months 244.84 
YKC — M/18 11 months STUO 
AKM M/18 13 months 494.92 
CHL M/18 16 months 319.09 
^ F?22 19 months IfL53 
TCWJ M/12 24 months 215.69 
PTM M/16 24 months 789.23 
CCK FTTS 24 months 691.96 
LMC M/30 26 months 115.80 
SKW WTl 35 months 2 7 0 8 
O H MMO 36 months 245.75 
KCY M/10 2 ^ 0 
Y ^ WTl I^A3 
YLP f n i 5^L3l 
WCK M/12 290.60 
LWS M/13 6rL75 
L ^ M/14 326.03 
CLY M7l4 f 7 ^ 
C M . F/18 702.77 
TCT F/18 119.78 
K ^ m S 87.99 
T ^ M/20 81.75 
AMW M/21 • 289.75 
N ^ M/23 547.60 
OT W ^ 624.03 
LW F/36 — 67.56 
T Y ^ M/38 158.37 
Table 3.12. Plasma BALP-Adm of patients with at least three years 
follow-up period and their survival. 
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Figure 3.16 Boxplot of Plasma BALP at admission in osteosarcoma 
patients with three-year survival or died of disease 
within three years. 
Analysis is done by Student's t-test, p = 0.05, between the difference 
of survived patients (n = 16) and patients who died of disease (n = 
14). 
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Patient Code Sex>^ Age Tumor Volume (ml) * Plasma BALP-Adm (U/L) 
LDK fJn M 99.4 
BWY — F/12 150 r O ^ 
LYM “ F/12 160 Y07M 
KSW F7l4 300 1057.49 
HSF — F/26 2 ^ ^13¾" 
Tl M/10 i ^ 244.84 
YCY - M/13 — 135 133^ 9 
^ WYS 2l0 20^ 
Sffl] MTT? 200 7 L ^ 
CHW MTl7 M l 6 S ^ 
MCW M/21 M 790.01 
Table 3.13. Tumor volume and Plasma BALP-Adm of osteosarcoma 
patients 
* Tumour Volume is estimated from the MRI image of the patients 
using Ellipsoid Approximation. 
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Figure 3.17. Correlation of Plasma BALP at 
admission and the tumor volume of the osteosarcoma 
patients 
Linear Correlation coefficient = 0.3753 with p < 0.05 
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3.2.5.b.ii Detection oflocal recurrence and secondary metastasis 
For patients with local recurrence or metastasis, blood samples were 
collected at the time of confirmation of the relapse. Figure 3.21. shows the 
change of plasma BALP levels in patients with local recurrence or metastasis 
during the preoperative chemotherapy and at follow-up period. All patients 
have their plasma BALP level elevated during relapse, some patients exhibited 
elevated plasma BALP even before clinical confirmation of local recurrence 
(TI & YCY). Patients with sharp raise of BALP at recurrence (MCW, PTM, 
LFH, SC & TI) also related to a poor outcome, all those patients died within 6 
month after the relapse. 
3.3 Alkaline Phosphatase Isozyme expression in Osteosarcoma 
3.3.1 Isoelectric point (pI) gradient in Isoelectric Focusing (IEF) gel 
The pI gradient of the IEF gel was determined by using internal protcin 
pI marker and is shown in Figure 3.22. 
3.3.2 ALP Isozyme Standard 
Placental ALP and liver-specific ALP were prepared from human 
placenta and human liver (obtained from postmortem patients). For placental 
ALP preparation, 24.6 g of fresh placental tissue was used. The percentage 
yield of placental ALP extracted is 16% and the final placental ALP standard 
with activity of3767 U/L, with specific activity of8189.86 U/L/mg of protein. 
For the liver ALP standard preparation, 15 g of human liver tissue was 
used. The percentage yield of extraction is around 10% with the final activity 
of300U/L and specific activity of 685 U/L/mg of protein. 
Cord blood plasma was used as the BALP Standard. This has a total 
ALP activity of72.87 U/L and BALP activity of66.82Uy0:.. 
103 
R6Gij|ir:-
3.3.3 Ectopic Expression of ALP in Extracts of Human Osteosarcoma 
Cell Line: U-2 OS and SaOS-2 
3.3.3.a Isoelectric Focusing Separation 
ALP isozymes were extracted from 2 human osteosarcoma cell lires, 
the U-2 OS and SaOS-2, as described in the methodology section. PALP and 
LALP standards were prepared as described in the previous section, and cord 
blood was used as BALP standard. All samples and standards were separated 
on an IEF gel. Figure 3.23 shows the IEF separation of ALP isozymes with 
various treatments. 
Preheating the sample at 65°C for 6 minutes will essentially denature all 
forms of ALP except the placental and germ cell ALP, which are very 
thermostable. On the other hand, 56°C heating for 10 min. will preferably 
denature the BALP activity as it is much more thermoliable than any other 
forms of ALP. 
In U-2 OS extracts (lane 12-14) and the placental ALP standard (lane 
10,11)’ heating ofthe samples at both 56�C and 65°C did not affect the ALP 
activity. Moreover, lane 10 to 14 has a similar position with pI value around 
4.4. 
In SaOS-2 extracts (lane 1-3) and cord blood (lane 4-5), the ALP 
expressed are thermoliable as the bands totally disappeared after the 56°C and 
65°C heating. Also, the position of the band in SaOS-2 extracts is identical to 
the main band in the cord blood sample with pI value of3.9. 
In the liver standard (lane 7-8), 56°C heat treatment only partially 
denatured its ALP activity as the lane 8 only shows reduction of intensity. 
Complete denaturation of the ALP activity was only observed in the 65°C heat 
treatment method. Moreover, the band position of liver ALP standard is 
different from the BALP in cord blood and placental ALP standard with pI 
value around 3.7. 
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Patient Code Sex/Age Group* Tumor Necrosis 
YSM "M/11 一 REMAIN 100% 
WCK — M / 1 2 一 REMAIN 50% 
LWS —M/13 REMAIN — 90% 
PTM ~M/16 “ REMAIN 50% 
CCK — F / 1 8 “ REMAIN 60% 
CHL — M / 1 8 - REMAIN 20% 
YKC ~M / 1 8 REMAIN 一 4 0 % 
AKM —M/18 REMAIN — 0% 
AMW —M/21 REMAIN 一 90% 
MCW — M / 2 1 — REMAIN Q% 
KP ~ F / 2 2 REMAIN — 50% 
MSK — M / 2 3 一 REMAIN 80% 
SC — M / 2 4 — R E M A I N ~ 0% 
HSF ~ F / 2 6 REMAIN — 53.80% 
CY —F/30 REMAIN 100% 
LMC M/30 一 R E M A I N ~ 0% 
LFH M/40 — R E M A I N ~ 44% 
WCW — M / 4 5 — REMAIN 16% 
LCS M/51 “ R E M A I N ~ 50% 
CKL — F / 9 DROP 58.60% 
KCY M/10 - DROP 100% 
Tl M/10 — DROP 50.80% 
LDK — F / 1 1 DROP 82.40% 
SKW M/11 一 DROP 31% 
YLP F/12 一 DROP 95% 
BWY F/12 — DROP 71.75% 
LYM F/12 — DROP 95.50% 
TCWJ —M/12 DROP — 22% 
YCY M/13 ~ DROP 83% 
LKH M/14 — DROP 1 0 ^ 
CHW M/17 — DROP 80% 
SHL M/17 — DROP 6 ^ 
CML |F/18 DROP 100% 
Table 3.14. Tumour necrosis of the osteosarcoma patient in the 
"DROP" and "REMAIN" group. 
*"DROP" and ‘‘REMAIN’ is classified by comparing the plasma 
BALP level after preoperative chemotherapy with the age matched 
normal reference (N1 < 217.7 U/L; N2 < 136.8UyTL; N3 < 59.5U/L) 
with "DROP" group lower than the normal and "REMAIN" group 
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Figure 3.18. Boxplot of degree of tumor necrosis in patients with 
(DROP group) and without (REAMIN group) of 
plasma BALP levels during chemotherapy. 
Analysis is done by Student's t-test, p<0.05, between the 
difference of "DROP" group (n = 14) and the "REAMm" 









































































































































































































































































































































































































































































































































































































































































































3.3.3.b Biochemical Differentiation ofALP extracts 
Heat inactivation at 56°C and 65°C studies on the ALP extract from the 
2 cell lines were compared with the placental ALP standard in Figure 3.24 and 
Figure 3.25 respectively. ALP expressed in Sa OS-2 cells was inactivated 
only after a short term ofheating，especially with 65°C heating. On the other 
hand, ALP expressed in U-2 OS cell show only moderate heat inactivation 
even at 65°C heating, this is similar to the placental ALP standard. 
Results of the levamisole and L-phenylalanine inhibition studies were 
shown in Figure 3.26 and Figure 3.27 respectively. In the levamisole 
inhibition study, ALP expressed in SaOS-2 is highly sensitive to the inhibition 
of levamisole with complete inhibition by 1 mM oflevamisole. Both placental 
ALP and ALP expressed in U-2 OS also show inhibition by levamisole, 
however the degree of inhibition is not as great as Sa-OS 2 ALP extracts. In 
L-phenylalanine inhibition study, ALP expressed in SaOS-2 is not as sensitive 
to this inhibitor as in the placental ALP standard (2 mM of 50% inhibition) 
and U2 OS extracts. 
3.3.4 Alkaline Phosphatase Expression in Osteosarcoma Patient Plasma 
Sample 
Plasma sample of the osteosarcoma patients collected at admission was 
separated by IEF and the isozyme pattem was observed as described in 
methodology. Figure 3.28 shows the separation of 4 plasma samples. 
All plasma samples show 2 bands upon staining with a-naphthyl 
phosphate coupled with diazonium salt. However, for placental ALP and 
Bone ALP standard, only one band is observed. In 65°C pre-heating of die 
samples, all ALP bands disappeared (Figure 3.28B) in the plasma samples. By 
comparing with the BALP standard, the 2 bands in the plasma sample were 
identified as BALP and LALP. This is also confirmed by levamisole 
inhibition studies (Figure 3.28C). With the addition of 0.06mM levamisole 
into the staining solution, all ALP bands in the plasma samples reduced in 
intensity even when doubling the incubation time. Moreover lane 11 (BWY) 
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shows an extra band on prolonged staining with levamisole inhibition. This 
band compared with the placental ALP standard running on the same gel, 
exhibited a higher pI value (around 5) and was identified as intestinal ALP. 
3.3.5 Alkaline phosphatase isozyme expression in human osteosarcoma 
biopsy tissue 
ALP was extracted from the tissue of a few patients' samples collected 
during the biopsy was done and IEF gel separation as described in 
methodology section was done. The expression of ALP in 12 patient's tissue 
ALP extracts was shown in Figure 3.29. By comparing the PALP, BALP and 
LALP standard parallel, only BALP isozyme expression was found in human 
osteosarcoma tissue ALP extracts. 
3.3.6 Ectopic Expression of placental ALP in Human Osteosarcoma by 
Immunohistochemistry 
3.3.6.a Ectopic expression of placental ALP in human osteosarcoma cell 
line U-2 OS 
We have demonstrated that there is ectopic expression of PALP in 
human osteosarcoma cell line. By employing the immunohistochemistry 
technique with monoclonal antibody against human PALP, positive signal was 
observed in our seeded U-2 OS cell (Figure 3.30). This result was confirmed 
by comparing with the negative control (human liver tissue sections) and the 
positive control (human placenta tissue section) shown in Figure 3.31. 
Positive results were represented by the reddish brown precipitation 
formation. For the human placenta tissue sections, the cells were heavily 
stained into dark brown (Fig. 3.31A). For the human liver sections, since the 
primary antibodies have not cross-reactivity with the liver ALP isozyme, rhe 
section did not show any brown precipitation (Fig. 3.31B). For the U-2 OS 
cells, brown precipitation was observed and mainly found in the plasma 
membrane of the cells, but occasionally some of the cells nucleus were also 
highlighted (Figure 3.30A). 
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For the Sa OS-2 cells (Figure 3.32), there was no brown precipitation 
formation was found in both the slice with (Fig 3.32A) or without (Fig. 3.32B) 
the primary antibody incubation, thus without the expression ofplacental ALP 
isozyme. 
3.3.6.b Ectopic expression of placental ALP in human osteosarcoma 
tissue sections 
In our 7 osteosarcoma tissues obtained, they all show negative results in 
the immunohistostaining, i.e. without the brown precipitation formation, 
compared with the positive and negative controls. Figure 3.33 & 3.34 shows 
the H&E staining and the immunohistostaining ofPALP in two of the patients' 
(CSL, WCW) sections. 
For CSL, osteosarcoma tissue was obtained in biopsy and the H&E 
staining (Fig. 3.33A) shown dense population of cancer cells, heavily stained 
to dark blue with hematoxylene. For immunohistostaining, both the sections 
with (Fig. 3.33C) or without (Fig. 3.33B) primary antibody incubation, tLere 
was not brown color observed and therefore did not shown placental ALP 
expression. 
For WCW, the H&E staining (Fig. 3.34A) shows the dense populated 
osteosarcoma cells and the lace-like osteoid produced (stained into red) by the 
cancer cells. Again, the immunohistostaining of patient's tissue sections show 
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Figure 3.22. pI gradients of Agarose IEF gel 
pI of the gel was determined by the protein marker ofknown pI 
value and stain with Comassie Blue 
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Figure 3.23 IEF separartion of ALP isozymes from various 
sources. 
Lanel,2,3: SaOS-2 extract; Lane 4,5,6: cord blood; Lane 7,8,9: 
Liver ALP; Lane 10,11: placental ALP; Lane 12,13,14: U20S 
extract; Lane 2,5,8,13 sample preheated at 56�C for 10 min; Lane 
3,6,9,11,14 sample preheated at 65°C for 6 min 
ALP bands were visulized with its own enzyme activity by adding 
a-naphthyl-phosphate couple with diazonium salt, products are 
insoluble reddish brown precipiate. 
The pH gradient of the gel was determined by the protein pI 
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Figure 3.28. IEF separation of osteosarcoma patient plasma samples 
(A) No pre-treatment; (B) Samples pre-heating at 
65°C; (C) Staining solution containing 0.06 (iM 
Levamisole. 
Lane 1,5,9: Plasma sample from YCY; Lane 2,6,10: 
Plasma sample from LYM; Lane 3,7,11: Plasma sample 
from BWY; Lane 4,8,12: Plasma sample from HHW, 
Lane 13: placental ALP standard 
All samples added were diluted to around lOOU/L before 
the separation 
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Figure 3.29. IEF separation of osteosarcoma tissue ALP extracts 
Lane 1: Placental ALP standard; Lane 2: BWY ALP 
extract; Lane 3: KSW ALP extracts; Lane 4: MCW ALP 
extract; Lane 5: SHL ALP extracts; Lane 6: MLK ALP 
extract; Lane 7: Liver ALP standard; Lane 8: CMS ALP 
extract; Lane 9: LDK ALP extract; Lane 10: YCY ALP 
extract; Lane 11: WCW ALP extract; Lane 12: CKL ALP 
extract; Lane 13: HSF ALP extract; Lane 14: HHW ALP 
extract; Lane 15: BALP standard. 
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Figure 3.30. Photographs showing the immunohistostaining of 
placental ALP on seeded U-2 OS cells, using 
monoclonal antibody against human placental ALP as 
primary antibody (x200, counterstain by 
hematoxylene). 
(A) With ovemight incubation of primary antibody. 
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Figure 3.31. Photographs showing the immunohistostaining of 
placental ALP, using monoclonal antibody against 
human placental ALP as primary antibody on : 
(A) Human placenta tissue section (x200) 
(B) Human liver tissue section (x200) 
All sections counterstain with hematoxylin 
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Figure 3.32. Photographs showing the immunohistostaining of 
placental ALP on seeded Sa-OS-2 cells, using 
monoclonal antibody against human placental ALP as 
primary antibody (x200, counterstain by 
hematoxylene). 
(A) With ovemight incubation of primary antibody. 
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Figure 3.33. Photographs showing the H&E and immuno-
histostaining of placental ALP (counterstain with 
hematoxylin) on patient CSL osteosarcoma tissue 
sections. (xlOO) 
(A) H&E staining 
(B) With overnight incubation of primary antibody 
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Figure 3.34. Photographs showing the H&E and immuno-
histostaining of placental ALP (counterstain with 
hematoxylin) on patient WCW osteosarcoma tissue 
sections. (xlOO) 
(A) H&E staining 
(B) With overnight incubation of primary antibody 











































































































































































W ^ ^ ^ M U m  ^ ^ ^ ^ B S W M  ^^ins 
127
 
Chapter Four: Discussion 
DiGcurr-c-ion 
4. Discussion 
In the 1960s, osteosarcoma was considered as an incurable disease. 
Even with complete local tumor control by amputation, the survival rate of 
osteosarcoma was still a disappointing 20%. Multiple metastasis was the most 
commonly encountered problem and it nearly always led to an extremely poor 
outcome and early death. 
It was not until the introduction of multiple drug regime in 1970s, i.e. 
the use of several chemotherapy drugs spontaneously for cancer treatment, that 
the disease free survival rate were improved dramatically. The use of both 
neoadjuvant and adjuvant chemotherapy successfully eliminates 
mircometastasis to the lung and to other areas. In addition, chemotherapy can 
create a more clearly surgical margin around the tumor, making limb-sparing 
surgeries possible. With all these recent advances in treatment of 
osteosarcoma, both the clinical and functional outcomes of osteosarcoma 
� . . — ^-—— '--"''d_ 
patient are greatly improved. 
With increasing long-term survival rates in osteosarcoma patients, 
monitoring of the disease progression now becomes very important and raises 
the need for a sensitive biochemical marker of the disease. Such a sensitive 
biochemical marker not only can allow close monitoring of the treatment 
progress but also helps diagnosis and provides several prognostic insights into 
the disease. 
Up to date, the most commonly used biochemical marker in 
osteosarcoma is the plasma total ALP. As a biochemical marker, ALP has the 
advantage of easy and well define methods of measurement and is readily 
detectable in either serum or plasma samples. Many investigators demonstrated 
that plasma total ALP activity has prognostic values (Bacci et al., 1995) and 
can closely reflect the treatment progress of the disease (Davie et. al., 1991). 
Despite of these encouraging findings, plasma total ALP measurement 
has its own limitation: its level is greatly affected by other factors. Circulating 
plasma ALP is mainly contributed by two sources: the liver origin and the bone 
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origin. Thus, measured plasma total ALP level is the reflection of these two 
ALP isoforms. In osteosarcoma patients, bone ALP isoform is usually 
elevated and therefore allowing the total ALP level to be used as a biochemical 
marker. However, in patients with liver disease or having liver toxicity during 
the chemotherapy, the plasma total ALP level will also be elevated by the liver 
ALP isoform. This elevation will lead to a misleading estimation of the 
disease. 
Measurement of the plasma BALP alone will avoid this misleading 
result. In the past, the use of plasma BALP measurement is primary limited by 
the difficulty in differentiate it from the liver ALP isoform. Only semi-
quantitative measurement of plasma BALP is possible by heat inactivation at 
56°C and 65°C. An improved method of plasma BALP measurement is now 
possible by WGL precipitation method (Rosalki & Foo, 1984) and also the 
newly developed ELISA kit using monoclonal antibodies against the human ,—^  
" • • .. Z . . f l .»*、 
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bone-specific ALP. The availability of these improved methods of plasma 
BALP measurement give scientists chance to explore the clinical usefulness of 
this newly developed marker in osteosarcoma. 
A total of 49 osteosarcoma patients were recruited for our study. The 
age and sex distribution of the patients is shown in Figure 3.1. In our series, 
the tumor occurred more often in males, with more than half (65.3%), which 
agrees with the general male predominance in most other studies (Dahlin, 
1986; Campanacci, 1990; Huvos, 1991). In addition, affliction of the young is 
also observed in which most cases occurred in the second decade of life 
(61.2% of total occurrence). Concerning the site of osteosarcoma, most of the 
affected sites are around the actively growing physeal plate (knee joint area, 
i.e. the distal femur and the proximal tibia). 
With respect to the above descriptions, the general information of the 
osteosarcoma patients in the local Chinese population matches the descriptions 
with the results obtained in most of the studies conducted in other countries. 
129 
Dlc-cijc-c-ion 
Measurement of plasma BALP was done by several methods in this 
study. In order to compare the data measured by different methods, the 
correlation of different measurements were done and shown in Figure 3.2 a.id 
Figure 3.3. All data were converted into unit, which is compatible to 
ALKPHASE-B® ELISA kit. High correlation was found in the ABBOTT 
methods Vs. ALKPHASE-B method and the COBAS MIRA method with the 
ALKPHASE-B® methods, with both R^ above 0.9. 
Since the use of plasma BALP measurement is not popular in Hong 
Kong, there is no normal reference range of plasma BALP in local Chinese 
population. Leung, et al in 1993 established the normal reference for the local 
Chinese population. In that study, they showed that the plasma BALP activity 
in normal Chinese children is high in children, declines rapidly in adolescence 
and remains low in adults. The mean value of the plasma BALP activity for 
adult males is 39.76 土 16.68 U/L and for adult females is 31.36 士 12.41 U/0 .^ 
——^v 
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The range is 23 to 56 VfL. However, in that study, only the normal refere:ice 
for adults was established. Since most of the osteosarcoma patients are 
children or teenagers, comparison of their plasma BALP level with the adult 
normal reference will be inappropriate. Nevertheless, the plasma BALP 
activity in children and in adolescence has to be reestablished. 
The normal reference of the local Chinese population in differenct age 
groups is listed in Table 3.4. Normal is defined as “no past history or present 
sign or symptoms of liver or metabolic bone diseases". Normal subjects were 
divided into 3 groups according to their ages. The three groups are N1 with 
age below 12，N2 with age between 12 to 16 and N3 with age above 16. The 
definition of above age groups depends on the normal growth of man, with 2nd 
sexual development at about age 12 and reach maturity at about age 16. Thf.re 
is significant difference in normal reference of the three age groups, with 
highest values in childhood then adolescence and lowest in adults (Figure 3.4). 
Since BALP is an important enzyme responsible in bone formation, the 
elevation of plasma BALP in children and adolescence reflects their active 
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growth periods in the skeletal structure. In addition, since the normal plasma 
BALP level in different age group are significantly different from each other, it 
is important for us to compare the plasma BALP level in osteosarcoma patients 
with an age-matched normal reference. 
Plasma BALP level at admission was used to represent the initial BALP 
level of the patient before any treatment. When we compared the plasma 
BALP-adm with the normal subject independent of age group, we found that 
plasma BALP-adm is significantly higher than the normal plasma BALP. 
Similar results were obtained when using plasma total ALP-adm level. When 
plasma BALP-adm of patients were compared with age-matched normal 
groups, significant differences were only found in T2 (p < 0.01) and T3 Qp < 
0.001) groups (figure 3.7 & 3.8). Thus, plasma BALP-adm can be used as a 
diagnostic tool for patients with age above 12. 
For age below 12, there is no significant difference between the plasma 
、 _ “ :；> 
BALP level in normal subjects and the osteosarcoma patients (Figure 3.6). It 
may be due to the fact that the plasma BALP level in this age group is already 
very high, the increase of the plasma BALP in osteosarcoma patients is not so 
significant with the initial high baseline value. Thus, plasma BALP-adm rray 
not be a good diagnostic tumor marker as in other age groups. 
Compared with the normal subjects, plasma TALP-adm level of the 
patients are also significantly higher than the normal, independent of age. 
However when age-matched comparison was performed, significant difference 
in plasma TALP can only be demonstrated in T3 group (Figure 3.12). In other 
2 age groups, plasma TALP level fails to show a statistically significant 
difference between the normal and the patients. Thus, in term of a diagnostic 
tool for osteosarcoma, plasma BALP level is more sensitive than using just the 
total plasma ALP level. 
To improve the disease-free survival, it would be important to identify 
patients with poor prognosis who could be treated with more aggressive 
therapy. Pretreatment plasma total ALP level is considered as one of che 
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prognostic factors of osteosarcoma (Bacci et, aL, 1993). Patient with increased 
pretreatment plasma ALP level is significantly higher in the metastatic group 
than in the group of patients with localized disease. Moreover, among patients 
with elevated plasma TALP levels, the percentage of relapses was higher in 
patients with high levels of the enzyme in comparison with patients with 
moderately elevated values. 
The possibility of using plasma BALP-adm for prognosis assessment is 
investigated. Plasma BALP-adm successfully reflects patients with higher 
chance of local recurrence and longer survival periods. Patients with locnl 
recurrence of osteosarcoma after operation removal of the lesion have 
significantly higher plasma BALP-adm value compared with the non-
recurrence patients (Figure 3.13). 
In addition, the plasma BALP-adm levels were compared with respect 
to the survival rate of the patients. The plasma BALP-adm of patients whose 
〜 — .广厂’ r . 、 
passed away within 3 years, had significantly higher plasma ALP-adm level 
compared with the disease-free patients. Moreover, the two tail significance 
difference of plasma BALP-adm gradually decreased with increasing survival 
years, indicated that the higher the plasma BALP-adm, the poorer the 
prognosis of the disease is. 
The plasma BALP-adm can directly reflect the tumor burden of the 
patients. Plasma BALP-adm shows a positive correlation with the tumor 
volume (Figure 3.17), i.e. with higher plasma BALP activity, the volume of 
the tumor is higher. Since the BALP is released directly from the tumor, it is 
reasonable to believe that with an increase in tumor volume, the amount of 
BALP produced by the tumor cell increased. However, though the correlation 
is significant, the correlation coefficient is only 0.6127. This, rather, poor 
correlation between the plasma BALP level and the tumor volume may be 
affected by the subtype ofthe tumor. Even with about half of the osteosarcoma 
cases are classified as "osteoblastic" (Dahlin, 1978), other subtype of 
osteosarcoma may not have large amount of bone production, sometime may 
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even be osteolytic. Moreover, the measurement of tumor volume include the 
whole lesion area, i.e. some part of measurement are the reactive zone of the 
tumor but not the tumor cell itself, leading to an over-estimation of the actual 
tumor volume. 
As an effective biochemical marker for tumor, perhaps the most 
important criteria are the use of the marker for the monitoring of the therapy 
and to answer the commonly asked questions: Can the marker tell the 
physician whether therapy has been effective? Does normalization of the 
marker indicate that all malignant disease has been eliminated? For plasma 
BALP, we demonstrated that it reflects the successfulness of the pre-operative 
chemotherapy. 
With a successful chemotherapy, most of the tumor cells should be kill 
by the chemotherapy drugs. Based on the histological studies of the resected 
specimen, the pathologist determines the percentage of necrosis of the tumor 
- - -AW*-
killed by the drugs. For patients with drops of plasma BALP level back within 
the age-matched normal range during the chemotherapy ("DROP" group), their 
degree of tumor necrosis is significantly higher than patients without the drops 
ofplasma BALP ("REMAIN" group). 
The use of plasma BALP to estimate the successfulness of the 
chemotherapy is important. It can provide a useful information to the physician 
or the surgeon about to tumor itself so to plan for a better regime for the 
patients. 
For patients with good responses toward the pre-operative 
chemotherapy (above 80% tumor necrosis), their elevated plasma BALP level 
significantly drops during the first few weeks of chemotherapy. In addition, ihe 
plasma BALP level always drops after the removal of the tumor (Figure 3.19). 
This drop of plasma BALP is not always observed in those patients with poor 
response to the chemotherapy (degree of tumor necrosis below 50%)(Figure 
3.20). In fact, most of poor response patients show no significant drops of 
plasma BALP, their plasma BALP, especially for patients with very high level 
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ofenzyme activity, show great fluctuations during the chemotherapy. In these 
patients, the clinical outcome is usually much poorer than the others. Patients 
KSW，SC and TI all have initial high and fluctuated plasma BALP activity. 
SC and TI passed away within half year of the operation and KSW died even 
before the operation removal of the tumor. Moreover, the plasma BALP level 
did not drop back to the normal range even after the surgical removal of the 
tumor. Since most of the BALP was produced by the tumor cells, the elevated 
plasma BALP after the operation may imply incomplete removal of the tumor 
or the presence of undetected metastases. In our 2 cases, the former reason 
should not be the case since pathological examination show clear margin ofthe 
resected specimen. Thus, the high plasma BALP level was most probably 
caused by the already metastases tumor cell which did not response to 
chemotherapy and have not been resected during the surgery. 
Plasma BALP level can be used to guide the response of the patients -— —^, 
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towards the chemotherapy. Patients with drops of the plasma BALP level 
usually have a better response toward the chemotherapy. On the other hand, 
patients which have a large fluctuation in plasma BALP level usually represent 
a more poor response toward the chemotherapy and extra care should be paid 
to those patients. Change of present chemotherapy regime should be 
considered. Plasma BALP level, after the surgical removal of the tumor, also 
play an important role in identify patients with high risk. If the patients' 
plasma BALP level did not drop back to normal reference even after the 
removal of the tumor, careful examination of the surgical margin to check the 
successfulness of the operation or any metastasis should be done. As 
demonstrated in TI case，his plasma BALP level did not drop back to normal 
range after first operation on the extremity but only after the surgical removal 
of the lung metastases. More efforts should be paid on the detection and 




Another important role of plasma BALP level is to detect early local 
relapse ofthe disease. Figure 3.21 shows that plasma BALP level raise during 
the detection of recurrence. Most of the patients with their plasma BALP level 
elevated above the normal reference during the time ofrelapse. For patients TI 
and YCY, the elevation of plasma BALP level were detected 2 months before 
the clinical confirmation of the local recurrence. However, not all elevation of 
the plasma BALP level during the follow-up periods necessarily implied local 
relapse. Bone reaction or fracture in the bone allograft may also lead to un 
raise in plasma BALP level. Thus, when encounter elevation in plasma BALP 
level, careful examination should be done to rule out other possibilities. 
In summary, plasma BALP is a good biochemical marker in 
osteosarcoma. The pretreatment plasma BALP level can provide diagnostic 
aid and also prognostic insight to the physician. In addition, the change of 
plasma BALP level during the pre-operative chemotherapy can reflect the 
-、— -—K 
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successfulness of the treatment and therefore provide important clue to"the" 
physician how the patients is responding and whether it is necessary to change 
the plan of treatment. Plasma BALP level is also a valuable tool in follow-up 
period as it can detect early metastasis and thus may allow an early treatment 
to the relapse. 
Placental ALP is synthesized in the syncytiotrophoblast cells of .he 
placenta from eight week of gestation throughout the pregnancy, which is 
distinct from the isozymes of other organs, and is found in the serum of 
pregnant women. In 1968, Fishman described the Regan isozymes, detected in 
the serum and tumor tissue of a patient with lung carcinoma that appears to be 
identical to the placental isozyme. Later, other isozymes of ALP were found to 
be tumor related and expressed in other carcinoma. However, no ectopic 
expression of any form of ALP is reported in osteosarcoma. 
In 1993, Stinson et al investigated the ALP mRNA expression in six 
human ostoesarcoma cell lines. He showed that 5 of the cell lines expressed 
only tissue-specific ALP mRNA. But in one of the cell line, U-2 OS, contains 
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a mixture of tissue non-specific ALP mRNA and at least one other form, 
indicated that there may ectopic expression of ALP in osteosarcoma. 
Therefore, we attempted to search for ectopic expression of ALP isozymes in 
osteosarcoma and try to explore any clinical uses of this ectopic expression. 
There is a wide range of techniques available for the characterization 
and quantification of multiple forms of ALPs. The techniques depend on the 
physiochemical properties, the nature of the catalytic site or the protein 
structure of the different isoforms and any post-translational modifications. 
These methods include gel electrophoresis, isoelectric focusing, affinity 
precipitation, chemical denaturation, heat inactivation, chemical inhibition, 
chromatography and immunoassay. In our studies, isoelectric focusing 
electrophosis was employed for the separation of the ALP in plasma and tissue 
extracts. Resolution of protein mixture is much higher in IEF than 
conventional gel electrophosis and can reveal the microheterogeneity of ALP � ：一 
isozymes (Rosendahl et. al., 1987). After the separation, the biochemical 
inhibition and heat inactivation properties of different ALP isozyme were 
explored for the characterization of ALP isozyme expression in plasma and 
tissue extracts. 
Isoelectric focusing (IEF) separates proteins according to their pI point. 
The pI gradients of the gel we are using are ranging from 2.5 to 9.5. However, 
the gradient of the gel is not uniformed. Since at extreme pH, i.e. pH 2.5 and 
9.5, the gradient of the gel is not stable. In order to stabilize the pH gradient of 
the gel and expanding the desired range of the pH gradients, we mix':d 
ampholyte with pH range from 3 to 5 with the preblending Pharmalyte® pH 
2.5 to 9.5. The pH gradient of the agarose IEF gel is shown in Figure 3.22. 
The pH gradient of the gel in pH range from 3.5 to 6.5 is quite even and the pH 
gradient sharply deepen after 6.5 since the addition of pharmalyte at pH 3 to 5 
have expanded the original pH gradient and pulling the alkaline pH gradients 
deeper. As most of the ALP isozymes have their pI values lies in the acidic 
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range (2.8 to 5.2), with this modification of the pH gradients, the separation of 
different ALP isozyme can be more clear. 
After the separation, ALP were directly visualized by it own enzyme 
activity, a-naphthyl phosphate were added in AMP buffer as substrate for 
ALP in which the product form couple with the diazo dye and form reddish 
brown insoluble complex. Heat inactivation and biochemical inhibition 
properties of different ALP isozyme were also employed together with IEF for 
the better characterization of ALP band visualized. Heating the sample in 
65°C will destroy all forms of ALP isozymes except the placental ALP and 
germ-cell ALP. Heating with 56°C will preferably denature the BALP isoform 
as it is extremely heat sensitive. Moreover in some of the IEF gel, levamisole 
was added to the staining solution as an inhibitor of both the bone and liver 
ALP, thus allowing the visualization of other low level expressed ALP 
isozyme. 
—, “. 、 
In Figure 3.23, we demonstrate the successfulness of the separation of 
different ALP isozyme standard prepared and also the cell extracts from the 2 
cell line, U-2 OS and SaOS-2. Since all extracts are prepared by releasing the 
ALP from the membrane by PIPLC, the microheterogenicity difference caused 
by the GPI anchor in ALP isozymes is minimized. 
Two human osteosarcoma cell line, U-2 OS and SaOS-2, were 
employed for the studies of the ectopic expression of ALP in osteosarcoma. 
ALP expression in SaOS-2 was well established, with sole production ofbone-
specific ALP fNakamura et al., 1988; Stinson et al., 1993). With large amount 
of BALP production in SaOS-2 cells, Farley et al in 1989 proposed that we 
could use the ALP extracts of this cell line as a standard for quantitative 
measurement of skeletal ALP activity in serum. Therefore we use this cell liue 
as a source of pure BALP standard for the expression of ALP in both the 
patients' plasma samples and the tissue extracts 
In order to confirm the expression ofBALP in SaOS-2 cells，cord blood 
was used as a source of BALP. Rosalki & Foo in 1993 demonstrated that more 
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than 95 % of the ALP found in the cord blood are ofbone origin. In lane 4 of 
Figure 3.23，one major band was observed in the acidic regions ofthe IEF gel. 
The BALP moved towards the anode and have pI value of around 3.9. This 
result is consistent with previous reports (Angellis et. al., 1976; Sinha et. al., 
1986; Rosendahl et. al., 1987). Sa OS-2 cell extracts also show a similar band 
in the same position. Moreover, the ALP pattern in SaOS-2 cell extracts have 
the same heat inactivation properties with the cord blood, after a short heating 
at 56°C, all the ALP activity in both samples disappeared. Comparing with the 
liver ALP standard prepared, complete deactivation of ALP only occur after 
65°C heating and the position of the band is located in a more acidic pH with 
pI around 3.5 to 3.7. We confirmed that the SaOS-2 human ostoesarcoma cell 
line we obtained expressed also only bone-specific ALP. 
After extraction, the ALP found in U-2 OS cell were found to be 
identical to placental or germ cell ALP. It has a similar electrophoretic 
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movement in the IEF gel with the placental standard prepared, which move 
toward the cathode and has pI value around 4.4 (Figure 2.23). Biochemical 
studies on the ALP extraction in U-2 OS, Sa OS-2 and the placental standard 
also demonstrate the ALP expressed in U-2 OS is heat-stable and sensitive to 
L-phenylalanine inhibition like that of placental ALP standard. Although the 
placental and the germ-cell ALP isozyme share many biochemical properties, 
they have different electrophortic movement in IEF gel (Rosendahl et al., 
1987). Thus, by comparing both the biochemical and electrophortic properties 
of ALP in U-2 OS and the placental standard, we concluded that the ALP 
expressed in U-2 OS ostoesarcoma cell line are placenta origin. 
With both human osteosarcoma cell lines, one of them has an ectopic 
expression of placental ALP and the other has only BALP expression. Note 
should be paid to the difference between these 2 cell lines. For SaOS-2, the 
osteosarcoma cell is more differentiated compare with the U-2 OS cells. 
Moreover, the BALP expression in SaOS-2 is about 100 times higher than that 
ofU-2 OS. U-2 OS were often refer to no expression of ALP (Manara et. al., 
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1996). Moreover, recent research found that U-2 OS has higher ability to form 
solid tumor in nude mice model comparing with SaOS-2 and the transfection 
of the active tissue non-specific gene back to the cell line reduce its 
aggressiveness of the cell line (Manara et al., 1996). Thus, the expression of 
the Regan isozyme may have a higher chance to occur in tumor with less 
differentiation and higher tumorgenicity. 
With the finding of ectopic expression of ALP in cultured osteosarcoma 
cell line, we postulated that ectopic expression may also found in osteosarcoma 
patients. We screen for the patients' pre-treatment plasma samples to search 
for the ectopic expression. Pretreatment plasma samples were used for the 
investigation to avoid the interference from the treatment to the patients. 
However, all pretreatment plasma samples show only elevated plasma BALP 
level and liver ALP (Figure 2.28). Sometimes, patients with blood group 0 or 
B, there may find the expression of intestinal ALP in the plasma as they are — - 一 . 
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active secretor of this enzyme. — 
The lack of ectopic expression finds in patients，plasma samples may 
imply: 
1) There is no ectopic expression of ALP in our osteosarcoma case ； or 
2) There is expression of ectopic ALP in our osteosarcoma cases but the 
expression is too low or it does not secrete into the body fluid. 
ALP is extracted in fresh human osteosarcoma tissues obtained in .he 
biopsy and then investigated using IEF (Figure 3.29). Results show in all 12 
patients osteosarcoma tissue collected, none of them have expression of ALP 
isozyme other than the BALP. In ALP extracts with very high BALP level, 
there are addition bands found in the alkaline region of the gel with pI values 
above 5. This fraction is not considered as ectopic expression of ALP as the 
band has the same properties with the BALP isoform: it is completely 
destroyed in 56°C heating and is inhibited in 0.06 mM of levamisole. In fact, 
several authors have described the finding of this additional band (Sinha et. aL, 
1986; Rosendahl et. al., 1987). This fraction often appeared when running 
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sample with high level of BALP activity. The location ofthe fractions at r>H 
around 5 indicates that they contain a smaller number of sialic acid residues 
than the bulk ofbone ALP fractions. 
Although ectopic expression of placental ALP was found in human 
osteosarcoma cell line, we cannot demonstrate the same expression in our 
osteosarcoma patients. The absence of ectopic expression of ALP can be 
explained by several postulations. The incidence of ectopic ALP expression 
maybe too low so with our limited samples collected, we cannot find any 
ectopic expression. Or ectopic expression in the cultured osteosarcoma cell 
line is just the differentiation change occur during the development of the cell 
line. There also have a chance that there is ectopic expression of ALP in our 
samples but the level is too low for our detection, especially after the long 
extraction process of ALP, this ectopic expression may be lost. 
To further confirm our finding, a more sensitive method, 
- « - .r 
immunohistostaining for the ectopic expression of placental ALP were 
employed. Monoclonal antibody against human placental ALP was used with 
specific affinity towards placental ALP but not other ALP isoforms. In other 
positive and negative controls using human placenta tissue section and human 
liver tissue section, we demonstrated that this antibody is specific to placental 
ALP and does not cross react with the liver ALP isozyme. 
Both the culture human osteosarcoma cell line and the paraffin sections 
of the osteosarcoma tissue were examined. In the 2 human osteosarcoma cell 
line, we confirmed our finding on the placental ALP expression in U-2 OS 
osteosarcoma cell. However, in the clinical osteosarcoma tissue sections, of ill 
7 paraffm blocks show no ectopic expression of placental ALP. We therefore 
concluded that there is no ectopic expression of placental ALP in our 
osteosarcoma samples. 
In an initial attempt to find a more specific biochemical marker for 
osteosarcoma, we try to explore any ectopic expression of ALP in 
osteosarcoma. Howevr, in all our clinical samples, both the tissue and the 
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plasma samples, there is no ectopic expression found. The lack of ectopic 
expression may be results of limitation in the number of samples collected. 
Even with the finding of these placental ALP expression in osteosarcoma in 
continuation of the project, the use of it as a biochemical marker is not a gojd 
choice due to it low incidence of expression. We therefore concluded that the 
search for the ectopic expression of ALP and the use of it as a biochemical 
marker is unsuccessful. 
” ' - -f 
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5. Conclusion 
5.1 Plasma bone-specific ALP as biochemical marker of osteosarcoma. 
As stated in the introduction sections, biochemical chemical marker of 
the tumor should satisfy a number of requirements. We try to evaluate the 
usefulness of plasma BALP as a biochemical marker in osteosarcoma 
following these requirements. BALP is produced by the tumor cells and is 
readily detectable in body fluid. Quantitative measurement ofplasma BALP 
level is now possible by employing an monoclonal antibody capture assay, the 
ALKPHASE-B®, with only very low cross influence with the LALP (5%). 
With these newly developed ELISA kit, the lowest possible detection level of 
plasma BALP is 0.7 U/L. 
Plasma BALP level at admission shows significant diagnostic and 
prognostic value in osteosarcoma. When plasma BALP-adm was compared to 
the normal reference of plasma BALP level obtained in local Chinese 
population, it is significantly higher in osteosarcoma patients then in normal 
subjects with age above 12，where the highest incidence of osteosarcoma 
occurred. 
In addition, plasma BALP-adm plays an important prognostic role in 
osteosarcoma. In term of long term survival of the patients, a high initial 
plasma BALP value indicated a much poor clinical outcomes. Patients w;di 
longer disease free survival period show significantly lower plasma BALP-
adm. In addition, plasma BALP-adm can identify the patients with higher 
chance of local recurrence after the operative removal of the osteosarcoma. 
Significantly higher plasma BALP-adm value was found in the recurrence 
group than the non-recurrence patients. These predictions provide valuable 
information to the clinician so that they may highlight the so call "high risk" 
patients and plan for a more aggressive therapy to improve the clinical 
outcome of these patients. 
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In term of quantitative reflection of the bulk of malignancy, plasma 
BALP-adm direct reflects the tumor burden of the patients. We show that 
there is a positive correlation between the plasma BALP-adm with the turior 
volume, i.e. with higher plasma BALP activity, the volume of the tumor is 
higher. 
Most important of all, the change of plasma BALP level reflected the 
effectiveness of the treatment. It levels correlated well with the successfulness 
of the pre-operative chemotherapy. Normalization of plasma BALP occurred 
only after a successful chemotherapy, as indicated by the necrosis factor ofthe 
tumor, and after the surgical resection of the tumor. Plasma BALP level is 
also a valuable tool in follow-up period as it can detect early metastasis and 
thus may allow an early treatment to the relapse. 
We therefore strongly suggested that the plasma BALP measurement 
should performed as routine analysis in every cases of suspected osteosarcoma 
_ - -一. 
and in the follow-up clinic. 
5.2 ALP isozymes expression in osteosarcoma 
Ectopic expression of placental ALP was found in human osteosarcoma 
cell line U-2 OS by both the biochemical studies and IEF analysis. The ALP 
expressed in this cell line is different from SaOS-2 cell line that is known for 
the sole expression of BALP. ALP expressed in U-2 OS cells show stability 
in 56°C and 65°C heating, L-phenylalanine sensitivity but insensitive to 
levamisole inhibition. Moreover, upon the separation by IEF, ALP expressed 
in U-2 OS shows similar band position with the placental ALP standard 
prepared. The ectopic expression of the placental ALP in cell line U-2 OS is 
further confirmed by our immunohistostaining result. 
In search of any ectopic expression ALP in our osteosarcoma patients, 
we found that none of the 14 patients we examine show any ectopic 
expression of ALP in both the plasma and tissue samples extracts. Moreover, 
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for immunohistostaining of placental ALP by using monoclonal antibody, all 
of the 7 samples examined did not show any expression ofthis enzyme. The 
lack of ectopic expression may due to the insufficient samples available for 
analysis, or the ectopic expression in the human osteosarcoma cell line is only 
a derepression of gene during the adaptation period ofcell line establishment. 
—� -—;"  
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ROCHE ALP IFCC reagent 
4-Nitrophenyl phosphate 16 mM 
Aminomethylpropanol pH 10.4 0.35 mM 
HEDTA 2 mM 
Magnesium acetate 2 mM 
Zinc sulfate 1 niM 
A-Gent® Alkaline Phosphatase Reagent 
p-Nitrophenyl Phosphoric Acid, 
[Bis(2-amino-2-ethyl-l,3-propanediol)Salt] 18 mM 
Magnesium 0.5 mM 
2 amino-2-methyl-1,3-propanediol 983 mM 
Phosphate Buffered Saline, PBS (pH 7.4) 
NaCl 140 mM 
KC1 2.7 mM 
KH2PO4 1.5 mM 
Na2HPO4 8.1 mM 
Cell Washing Buffer (pH 7.6) 
Tris-HCl lOmM 
MgCl26H2O 1 mM 
ZnCl2 0.1 mM 
NaCl 150mM 
ALP Extraction Buffer (pH 7.6) 
Tris-HCl 100 mM 
MgCl2.6H2O 0.1 mM 
ZnC12 0.02 mM 
Triton X-100 1% (w/v) 
clxix 
IEF-MIX 3.6-9.3 (Sigma I-3018) 
Compound pI value 
Amyloglucosidase 3 g 
Trypsin Inhibitor 4.6 
3-Lactoglobulin A 5.1 
Carbonic Andydrase II 5.9 
Carbonic Anhydrase I 5.6 
Myoglobin 6.8,7.2 
Lectin 8.2, 8.6，8.8 
Trysinogen 9.3 
lOO i^l double distilled H2O was used for reconsitution for each bottle of 
marker to give a protein concentration o f 2 mg/ml. 
Routine Procedure for Hematoxylin and Eosin Staining. 
Xylene 5 min. 
Xylene 5 min. 
100% Ethanol 2min. 
95% Ethanol 2min. 
85% Ethanol 2 min. 
70% Ethanol 2 min. 
Running tape water 1 min. 
Hematoxylin 8 min. 
1% Acid alcohol 1 sec 
Running tape water 1 min 
Scott's Water 2 min. 
Running tape water 1 min 
Eosin 1 min 
Running tape water 1 sec 
70% Ethanol lOsec 
85% Ethanol lOsec 
95% Ethanol lOsec 
95% Ethanol 10 sec 
100% Ethanol 2min. 
100% Ethanol 3 min. 
Xylene 5 min. 
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